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ABSTRACT 
 
Background: Schistosomiasis is a devastating parasitic disease. The mainstay of 
schistosomiasis control is by praziquantel treatment. The study aimed to determine benefits 
of repeated annual chemotherapy of schistosomiasis on development of protective immunity 
in school children in a selected endemic rural area in Zimbabwe and evaluate acute phase 
proteins and IL-6 as markers of inflammation. It is fundamental to evaluate the inflammatory 
markers and antibody profiles in the context of S. haematobium infection in school children 
in endemic settings in order to identify markers that predispose or protect them from 
infections. Acute phase proteins are plasma proteins whose concentration increases or 
decreases as a result of infection or inflammation and their production is stimulated by IL-6. 
Their circulating concentrations in the body reflect the extent of inflammation. There is an 
increased risk of cases of direct and indirect morbidities as a result of stimulation of tissue- 
destructive inflammation from S. haematobium infection, hence the need to determine the 
levels of inflammatory markers in S. haematobium infected and uninfected children and also 
determine the effect of annual repeated praziquantel treatment on levels of IL-6 and acute 
phase proteins. 
Methods: Urine specimens from 212 school children (7-13 years) were collected and 
examined to determine prevalence and intensity of S.haematobium infection at baseline, 6 
weeks and 2 years following annual rounds of praziquantel treatment. The overall rate of 
reinfection was determined after 2 years. Blood samples from the participants were assayed 
for total and S. haematobium (Sh13)-specific antibodies using the multi-plex magnetic bead–
based immuno-assays and sandwich ELISA, respectively before and 2 years after annual 
rounds of treatment. Levels of 4 acute phase proteins (ferritin, fibrinogen, procalcitonin and 
tissue plasminogen activator) were also measured from serum samples from the school 
xvii 
 
children using the magnetic bead–based immuno-assays at baseline and 2 years following 
praziquantel treatment. Sandwich ELISA was used to determine levels of IL-6 before and 
after treatment with praziquantel. 
 
Results: Annual treatment with praziquantel reduced the prevalence of S. haematobium 
infection (p<0.05) from 23.1% at baseline to 0.47 % after 2 years. Overall cure rate was 
97.8 %. Intensity of S. haematobium infected children declined (p<0.05) from 15.9 eggs/10ml 
urine at baseline to 2 eggs/10ml urine. After two years, overall rate of reinfection was 0.96 %. 
At baseline, total IgG4 was higher in S. haematobium infected children (p=0.042), while all 
other immunoglobulins were within normal ranges. There was an increase in total IgG2 
(p=0.044) levels and a decrease in total IgG4 (p=0.031) levels 2 years post-treatment; and no 
significant changes in other total immunoglobulins. Schistosoma infected children at baseline 
had an increase in anti-S. haematobium 13 IgG1 (p=0.005) and a decrease in S. haematobium 
13 IgG4 levels (p=0.012) following treatment. S. haematobium infected children had 
marginally higher levels of procalcitonin and tissue plasminogen activator before treatment 
though the difference of the two was not significant p>0.05-using the Mann-Whitney non-
parametricU test. Levels of ferritin and fibrinogen were lower in S haematobium infected 
children before treatment, however the difference was also not significant p>0.05-using the 
Mann-Whitney non-parametric U test.There was no association between infection status or 
IL6 and the levels of acute phase proteins p>0.05 for all acute phase proteins using the Mann-
Whitney non-parametric U test at baseline and post treatment. 
 
Discussion and Conclusion: Annual praziquantel treatment delivered to school children over 
2 years significantly reduced prevalence, intensity of infection and reinfection of S. 
haematobium infection. Treatment was also observed to cause a reduction in Schistosoma-
xviii 
 
specific blocking IgG4 and an increase in Schistosoma-specific protecting IgG1. Findings 
from this study suggest no bearing of S. haematobium infection status on level of acute phase 
proteins before and after treatment with praziquantel. The extent of inflammation cannot be 
determined using ferritin, tissue plasminogen activator and fibrinogen. Levels of IL-6 did not 
alter levels of the acute phase proteins. There is a need to explore other components in acute 
phase proteins as inflammatory markers in S. haematobium infections as well as explore other 
proinflammatory and anti-inflammatory cytokines. Findings from this study highlight the 
long term impact of the current Schistosomiasis control efforts which employ repeated Mass 
Drug Admintration of praziquantel on Schistosomiasis infection, reinfection and protective 
immunity. 
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CHAPTER 1: INTRODUCTION AND RATIONALE FOR THE RESEARCH 
 
This chapter covered the background information of the area being researched as well as 
relevant history on the study area. It also outlined the problem statement, study justification 
and purpose of the study. Study objectives and hypotheses were also covered. 
 
1.1 BACKGROUND 
Schistosomiasis commonly alluded to as bilharzia, is a devastating water-borne parasitic 
disease caused by infectious trematode worms of the genus Schistosoma [1]. It is prevalent in 
resource- limited settings and according to the World Health Organization (WHO), ranks 
second on the list of 18 Neglected Tropical Diseases (NTDs) [2]. Inadequate access to clean 
water coupled with poor sanitation are typical in such under privileged populations. 
Six species of schistosomes cause schistosomiasis in humans, and these are Schistosoma 
haematobium, S. mansoni, S. japonicum, S. mekongi, S. intercalatum and S. guineensis [2]. 
The distribution of the six species is defined by their host snails’ habitat range with each of 
the species having a specific range of different and suitable snail hosts. S mansoni uses 
aquatic freshwater Biomphalaria whilst S. haematobium, S intercalatum and S. guieensis 
employ the Bulinus snails. S. japonicum uses amphibious freshwater Oncomelania spp snails 
as its intermediate host and Tricula (Neotricula aperta) is used by S.Mekongi. S. 
haematobium, S japonicum and S. mansoni are the major species with an estimated 93% of 
all cases in the world concentrated in sub-Saharan Africa [3]. 
Schistosomes are classified in the phylum Platyhelminthes, however unlike most other 
platyhelminthes, schistosomes are dioecious and exhibit marked sexual dimorphism as adults, 
with the slender female fitted into the gynaecophoric canal of the male, producing eggs that 
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are fertilised by the male. The schistosomes can live up to 40 years residing within either the 
perivesicular (S. haematobium) or mesenteric (S. mansoni, S. japonicum, and others) venules, 
though their average life span is 3–10 years [4]. 
Adult worms derive most of their energy through anaerobic glycolysis by ingesting host 
erythrocytes and globulins [5]. Glucose and fatty acids derived from the host are used for egg 
production through fatty acid oxidation [6]. Schistosomes regurgitate waste into the 
bloodstream as they have no anus and cannot excrete waste products. Some blood and urine-
based diagnostic assays have made use of some of these excreted waste products [1]. 
1.1.1 Life cycle of schistosomes 
In order to control and eliminate human shistosomiasis it is essential to realize the 
schistosome lifecycle. The human host excretes Schistosoma eggs into a fresh water 
environment through urine or faeces and on hatching, the egg releases a miracidium, a free-
living and ciliated form, which remains infective for 6–12 hours. The miracidium swims 
towards the snail intermediate by ciliary movement and pierces its soft tissue, loses its cilia 
and develops into a mother sporocyst, which then produces daughter sporocysts through 
asexual reproduction. The sporocysts migrate to the hepatic and gonadal tissues of the snail 
and metamorphose into cercariae in 2-4 weeks [7]. The cercariae leave the snail intermediate 
host following light stimulation and swim through the water until they come into contact with 
human skin [8]. The cercariae penetrate the host skin using proteolytic enzymes and after 
shedding their tails, become young worms called schistosomula.The schistosomules leave the 
dermis via the venous or lymphatic vessels and migrate in the blood via the heart and lungs to 
the liver. These schistosomula mature in 4–6 weeks in the portal vein, mate, and migrate to 
the perivesicular or mesenteric venules [9]. 
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After mating the females produce a large number of eggs which secrete proteolytic enzymes 
to facilitate the migration of eggs into the lumen of the bladder (S. haematobium) or the 
intestine (S. mansoni, S. japonicum and the others). The eggs are either retained in host 
tissues where they induce inflammation  or are excreted into the environment through urine 
or faeces where those that reach freshwater will hatch and release the miracidia in fresh 
waters where the cycle commences all over again (Figure 1.1) [8]. 
 
 
Figure 1.1: Life Cycle of Schistosomes, retrived 02/08/17, (Adopted from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231879/figure/F2 
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1.1.2 Schistosomiasis Distribution 
1.1.2.1 Global Distribution 
S. haematobium is localised in Africa, India and the Middle East whilst S. mansoni is found 
in Central and West Africa, Egypt, Brazil, Venezuela, Madagascar and the West Indies. S. 
japonicum is found in China, Philippines and Indonesia whilst S. mekongi is found along, 
Mekongi river basin between Cambodia and Lao People’s Democratic Republic, parts of the 
Congo River and in lower Guinea on the African continent. S. guineensis and S. intercalatum 
are localised in West and Central Africa [10, 11, 12] (Figure1.2).  
 
Figure 1.2: Global distribution of Schistosomiasis, retrieved 12/8/17, (Adopted from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231879 
 
5 
 
1.1.2.2 Schistosomiasis distribution in Zimbabwe 
In Zimbabwe, schistosomiasis is predominant in the north, north-east, south east, and eastern 
regions, with 11 provinces being affected with a prevalence ranging from 3.3 to 39.3% 
amongst 10-15 year olds according to a survey by Midzi et al (2014) [13]. The prevalence of 
schistosomiasis is low in the entire western region of the country. The distribution (Figure 
1.3) is reflective of climatic conditions such as rain and temperature which are used in 
predicting infection risk and prevalence of schistosomiasis in non-surveyed areas [14]. 
 
Figure 1.3: Distribution of schistosomiasis in Zimbabwe, retrieved 04/09/17, (Adopted 
from Midzi et al, 2014) [13] 
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1.1.3 Diagnosis of Schistosomiasis 
Accurate diagnosis for schistosomiasis is necessary for swift treatment and control of the 
parasitic disease and should be inherent in all schistosomal control programmes. The earliest 
schistosomiasis diagnostic procedures involved parasitological detection of eggs in stool and 
urine samples and remain the gold standard for schistosomiasis diagnosis [15]. For intestinal 
schistosomiasis, WHO recommends the microscopy-based Kato-Katz thick stool smear 
technique for diagnosis of S. mansoni, S. japonicum, S. mekongi, and S. intercalatum and for 
the quantitative assessment of infection intensity [16]. 
Urine filtration and concentration of S. haematobium eggs, with subsequent microscopic 
examination is the main approach for urinary schistosomiasis diagnosis. Schistosome eggs 
are easy to detect and identify under a microscope owing to their oval shape with a sharp 
terminal spin. Immunodiagnostic techniques can be used to detect anti-schistosomal 
antibodies or circulating schistosomal antigens in plasma, serum, urine, or sputum. Many 
immunological tests are available for the diagnosis of schistosomiasis, with most techniques 
detecting IgG, IgM, or IgE against soluble worm antigen (SWA) or soluble egg antigen 
(SEA) by enzyme-linked immunosorbent assay (ELISA), indirect haemagglutination, or 
immunofluorescence [17]. Highly sensitive and specific PCR based assays (e.g. real-time 
quantitative PCR or multiplex PCR) have been developed for the detection of schistosome 
DNA or RNA in faeces or serum. Recent advances include the detection of egg DNA, 
circulating cell-free parasite DNA (CFPD), and circulating microRNAs [18]. 
1.1.4 Clinical Manifestations 
The initial human contact with schistosomes is usually followed up by a mild prickling 
sensation with rash at the site of cercarial penetration [19]. The host immune system mounts 
an attack against the cecariae that penetrate the skin consisting of specific immunoglobulin E 
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antibodies, eosinophils, and macrophages that fight against the schistosomula. Destruction of 
the schistosomula can occur, resulting in edema and massive cellular infiltrates which cause 
dermatitis marked by papules, erythema, vesicles, edema, and pruritus [20]. However, the 
schistosomula that survive the immune attack and will migrate inside the body depositing 
eggs causing a hypersensitivity reaction known as Katayama fever. The acute onset of 
Katayama fever is accompanied by sudden, flu-like symptoms such as fever, fatigue, 
myalgia, headache, and non-productive cough and is common in travellers and tourists to 
schistosomiasis-endemic areas. Chronic schistosomiasis is the most prevalent form of the 
disease in endemic areas and occurs as a result of prolonged exposure to infective cercariae. 
In these endemic areas, children encounter their first infections by the age of 2 years and the 
burden of infection increases in intensity until they are young adolescents after which a 
general decrease occurs in adulthood. Immune reactions to Schistosoma eggs trapped in the 
tissues in chronically infected cases ultimately result in inflammation in affected tissues 
followed by granuloma formation [21].The granuloma plays a protective role by preventing 
egg toxins and enzymes from coming into contact with tissues, however collagen deposits 
replace the granuloma as the immune response subsides [22]. The primary causes of 
morbidity in chronic Schistosoma infections are the large granulomas and fibrosis produced 
by the host's immune response against the Schistosoma eggs. The extent and severity of 
infection varies depending on the host genetics, intensity of infection and location of 
Schistosoma eggs and worms [7]. 
Deposition of S.haematobium eggs occurs in vesical and uteral walls resulting in 
inflammation that culminates in urinary schistosomiasis which is characterized by 
haematuria, dysuria, proteinuria, calcification in the bladder, obstruction of the ureter, renal 
colic, dark-coloured urine, and frequent and painful urination. Haematuria is so common in 
endemic areas that it is sometimes construed as a natural sign of puberty for boys and 
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confused with menses in girls [23]. Chronic infection may result in development of 
obstructive uropathy, renal failure, hydroureter, hydronephrosis, and bladder cancer [24, 25]. 
Intestinal schistosomiasis occurs as a result of inflammation caused by S. mansoni and S. 
japonicum eggs trapped in the walls of the large intestine and rectum. Symptoms include 
abdominal pain, diarrhoea and constipation. Bowel obstruction, appendicitis, and 
gastrointestinal perforation may develop in extreme cases [7]. 
Chronic inflammation caused by all Schistosoma species eggs trapped in tissues cause non-
specific morbidities such as anaemia, malnutrition, and impaired childhood development 
[26,27]. These Schistosoma- associated morbidities are commonly associated with moderate-
to-heavy egg-infection intensities and are progressive. School children and pre-school 
children are the most vulnerable groups to developing overt disease because of the higher 
rates of water-related activities, immunological status and anatomical vasculature [28, 29]. 
These groups harbour the largest numbers of adult worms, with copious tissue entrapped eggs 
causing systematic and organ-specific inflammation [1]. Fortunately, preventive 
chemotherapy through periodic large-scale administration of praziquantel (PZQ) to school 
children and other high-risk groups without prior diagnosis has resulted in suppressing the 
morbidities [16]. 
1.1.5 Control of Schistosomiasis 
The World Health Assembly resolution 54.19 urged all its member nations to be actively 
involved in the control and ultimately the elimination of schistosomisais [30]. 
Schistosomiasis can be controlled through the use of measures such as elimination of 
intermediate host snails, chemotherapy, basic sanitation and clean water supply, prevention of 
human contact with water containing infected snails and health education, either in isolation 
or in combination [31]. Chemotherapy using praziquantel as the drug of choice is the most 
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popular method of control because it significantly reduces morbidity caused by tissue-
deposited eggs and transmission by reducing contamination of snail habitats by Schistosoma 
eggs. The development of vaccines is an important alternative strategy for schistosomiasis 
control. However, no suitable vaccine has yet been developed for widespread use. By 2020, 
the global health community aims to control and eliminate human helminthiases, including 
schistosomiasis in selected African countries, principally by preventive chemotherapy 
through mass drug administration of antihelminthics [30]. 
1.1.5.1 Chemotherapy using Praziquantel 
Praziquantel, a pyrazino-isoquinoline derivative, is a WHO-endorsed drug that is highly 
efficacious, and has a broad spectrum against helminth infections [32]. It was discovered in 
1972 and is administered at the standard oral single dose of 40 mg/kg body weight [33]. Its 
mechanism of action is not yet fully understood though there is evidence suggesting that it 
increases the permeability of schistosome membranes to calcium there by promoting 
tegument damage and worm paralysis [34].  However, praziquantel is only active on adult 
worms but not on immature worms and thus follow up treatment may be required 4-6 weeks 
later [1]. There have been suggestions to combine praziquantel with antimalarial drugs 
(artemether, artesunate) possessing anti-schistosome properties of killing immature worms 
[35]. 
Approximately 80% of the drug is rapidly absorbed from the gastrointestinal tract and 
metabolized by the liver then excreted through the urine and faeces [36].The benefits of 
praziquantel are its high efficacy, ease of administration, relative safety, and mild to moderate 
side effects that include nausea, dizziness, rash, pruritus, headache, drowsiness, and 
abdominal pain [37]. Preventive chemotherapy is targeted toward school children in endemic 
areas because they are known to have a high risk of infection. In areas where the prevalence 
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of infection is at least 10%, preventive treatment should also be given to those who are at 
high risk of infection because of their occupation, such as fishermen, farmers, and irrigation 
workers, as well as women who may be exposed to infected waters when performing their 
domestic chores. Pregnant and lactating women in these areas are considered at high risk of 
developing morbidity due to schistosomiasis infection and should also be included in 
preventive chemotherapy campaigns [2]. 
The WHO estimated that the total number of people that required treatment for 
schistosomiasis was 218 million in 2015 with 92% living in the African region. The number 
of school children who received treatment for schistosomiasis during the same period was 46 
million representing 81.2% of the total number of people treated in the African region [38]. 
There has been a rising interest in the control and elimination of Neglected Tropical Diseases 
(NTDs), and currently the control of schistosomiasis is a priority for many governments, 
donors, pharmaceutical companies and international agencies. 
1.1.5.2 Mass Drug Administration 
Mass chemotherapy is a form of treatment whereby the entire population is treated without 
prior individual diagnosis.The mass drug administration aims to lessen morbidity and 
mortality due to Schistosoma infection and prevent new infections by limiting transmission 
through reduction of the overall prevalence in the population [39]. The assumption is that 
mass chemotherapy results in decreased excretion of Schistosoma eggs, contamination of the 
environment, and infection of the snail population, resulting in less source of infection for 
humans. The advantage of mass drug administration is low diagnostic cost and the simplicity 
of providing treatment in schools coupled to access to infrastructure within which such 
programs can operate successfully however, the high cost of drugs and the delivery system 
11 
 
may be the major constraints. Praziquantel has been the drug of choice in recent control 
efforts employing mass drug administration [32]. 
Even though praziquantel is efficient in eradicating active infection, it does not cure 
everyone. As a result rapid reinfections have been reported in communities where it is 
unavoidable to get in contact with water infested with snails carrying the S.haematobium 
larvae [40]. Reinfection cannot be prevented by mass drug administration, and infection rates 
tend to return to baseline values within 24 months after chemotherapy [41]. Hence, there is 
need to repeat mass treatments with a frequency dependant on the endemic risk level of the 
community.  
1.1.6 Antibody profiles and inflammation markers 
The immune system of infected hosts is constantly confronted by several life cycle stages of 
S.haematobium such as penetrating cercariae, adult worms and eggs [42]. The multitude of 
antigenic moieties the host encounter as a result, stimulate the humoral and cellular immune 
responses leading to antibody production and proliferation of specific T cells [43]. The roles 
of particular antibody isotypes in immune defence have been revealed in mostly in vitro 
studies. IgE has been linked to resistance to reinfection as it cooperates with mononuclear 
phagocytes, eosinophils, and platelets to kill Schistosoma larvae through antibody dependant 
cytotoxicity. Elevated S. haematobium specific IgE and tissue eosinophilia are crucial in 
developing resistance to schistosomiasis. Studies have identified IgG2 and IgG4 as blocking 
antibodies that prevent IgE from binding to eosinophils preventing antibody dependant 
killing of schistosomes. Praziquantel kills worms exposing internal antigens which in turn 
alter antibody profiles with changes in humoral and cell immune responses observed 
following the anti-helminthic administration [44].  
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The immune system tries to deal with the burden of Schistosoma worms and eggs, however 
the chronic inflammation resulting from soluble egg antigens released from tissue-trapped 
eggs is inevitable. Inflammation is a complex process that occurs as a result of vascular tissue 
responding to infection, exposure to toxins or cellular injury through production and 
accumulation of plasma proteins, leucocytes and cytokines [45]. The degree of inflammation 
reflects the extent of the S. haematobium infection and its resolution will result in the 
inflammed tissue returning to its status prior to the injury. In essence inflammation is meant 
to control parasitic infections but if left uncontrolled culminates in tissue injury.In some cases 
where the S. haematobium persists, resolution fails to take place leading to chronic 
inflammation however inflammation can still persist after the removal of the parasite [45].  
Chronic inflammation can be perceived as a consecutive series of separate inflammatory 
stimuli resulting in increased serum concentrations of acute phase proteins. The acute phase 
proteins are plasma proteins whose concentration increases or decreases as a result of 
inflammation or infection and are produced and released mainly by the liver to the systemic 
circulation mainly through the action of different proinflammatory cytokines (e.g., IL-6, IL-1 
and TNF-α). Interleukin-6 is the chief stimulator of the production of most acute phase 
proteins and is important in the regulation of the immune response, inflammation, and 
haematopoiesis [46]. It is fundamental to evaluate the inflammatory markers and antibody 
profiles in the context of S. haematobium infection in school children in endemic settings in 
order to identify markers that predispose or protect them from infections. Such information 
has vital implications in vaccine production which has been elusive in schistosomiasis. 
1.2 Problem statement 
The immunology of schistosomiasis is faced with challenges where currently there are no 
vaccines available and insufficient knowledge of dominant antigens for future development 
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of vaccine targets. To this end, understanding antibody profiles and inflammatory markers 
such as cytokines and acute phase proteins is necessary to limit the degree of 
immunopathology in schistosomiasis. Children residing in the same geographical location 
and exposed to similar water-related activities suffer different consequences with regards to 
S. haematobium infection.  Some are easily infected and reinfected whilst others never get 
infected. It is important to understand how this protection develops, both to aid vaccine 
development, and to understand the long-term implications of other control strategies which 
may reduce or alter natural exposure to the parasite. School children harbour the largest 
numbers of adult worms and tissue entrapped eggs causing systematic and organ-specific 
inflammation. If left untreated, the children will develop severe Schistosoma-related 
morbidities such as calcification in the bladder, obstruction of the ureter, renal colic and 
bladder cancer. Identifying children who are exposed to inflammatory mediators early in life 
allows for earlier treatment which prevents future health problems.Mass drug administration, 
which is the main strategy for control, does not prevent reinfection, and infection rates tend to 
return to baseline values within 24 months after chemotherapy. Hence, this strategy needs to 
be repeated with a frequency depending on the endemic risk level of the community.  
1.3 Hypotheses 
The following are the hypotheses of the study: 
 Protection and susceptibility to S. haematobium infections are related to presence of 
total and specific S. haematobium protective or blocking antibodies. 
 Repeated mass treatment with praziquantel alters the antibody profiles in both S. 
haematobium infected. 
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 Presence of inflammation markers is associated with S. haematobium infection status 
and repeated mass treatments with praziquantel modifies the level of the markers in 
both S. haematobium infected. 
 
1.4 Research questions 
Are there any variations in biochemical markers of inflammation and antibody levels in 
individuals on repeated annual praziquantel mass administration and is there any relationship 
between levels of inflammatory markers and antibodies with respect to resistance to 
infection/reinfection? 
1.5 The General objective 
The general objective of the study was to monitor antibody profiles, biochemical markers of 
inflammation through measurement of acute phase proteins and the proinflammatory 
cytokine, IL-6 in Schistosoma-infected, non-infected and re-infected individuals on repeated 
mass treatment with praziquantel. 
 
1.5.1 Specific objectives 
i. Determine consequences of praziquantel on S. haematobium prevalence, 
intensity of infection and reinfection rates and also assess the effect on the 
Schistosoma-induced morbidity-haematuria. 
ii. To determine the effect of total and Schistosoma-specific antibodies on 
protection or resistance to S. haematobium infection and evaluate the effect of 
praziquantel treatment on the antibody profiles. 
iii. To assess the usefulness of ferritin, fibrinogen, procalcitonin and tissue 
plasminogen activator as inflammatory markers in schistosomiasis and 
determine the effect of praziquantel treatment on their levels post treatment. 
iv. To investigate the effect of the proinflammatory cytokine IL-6 on acute phase 
proteins in Schistosoma infected and uninfected individuals, before treatment 
and after treatment with praziquantel. 
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CHAPTER 2: LITERATURE REVIEW 
This chapter covered the review of the area under study, current information and previous 
research that had been done with emphasis on relevance of our study. The scope included 
epidemiology, efficacy of praziquantel and its use in mass drug campaigns. Immune 
responses following treatment as well as the relationship between acute phase proteins and 
the pro-inflammatory cytokine IL-6 in schistosomiasis were also covered. 
The chapter also included some information (which was duly acknowledged) from our book 
chapter that was published in 2017. 
2.1 Epidemiology of Schistosomiasis 
Schistosomiasis is a deadly parasitic disease that remains as one of the most prevalent 
Neglected Tropical Diseases (NTDs). Worldwide, schistosomiasis is estimated to affect over 
290 million individuals [1], with more than 779 million individuals living in high-
transmission areas [2]. An estimated 120 million individuals have schistosomiasis-related 
symptoms and the disease accounts for over 2.8 million years lived with disabilities [1]. The 
disease caused by S. haematobium is the most prevalent form of schistosomiasis in Africa 
and the Middle East affecting approximately 107 million people [2]. Schistosomiasis is 
responsible for significant health problems and is a socioeconomic burden in most of Sub-
Saharan Africa and some other tropical countries. Schistosomiasis is endemic in Zimbabwe 
and in 2009 the disease was included in the 2009–2013 National Health Strategy by the 
Ministry of Health and Child Care underscoring the significance of appreciating the 
distribution and burden of the disease. A nationwide cross-sectional survey was conducted by 
Midzi et al (2014) [3] in order to map schistosomiasis because of its public health importance 
in Zimbabwe. 
19 
 
 In affected populations, school children harbour the highest number of eggs and intensity of 
schistosome infections, while a lower intensity of infection is observed in adults [4]. In 
children, urogenital schistosomiasis causes haematuria, dysuria, nutritional deficiencies, 
anaemia, growth retardation, decreased physical performance and impaired memory and 
cognition [5]. These factors combine to reduce school attendance and to impair educational 
performance, which, in turn, lead to a reduction in future productivity and wage-earning 
capacity [6]. 
2.2 Preventive Chemotherapy and Mass Drug Administration 
In order to control the burden of schistosomiasis it is necessary to improve sewage disposal, 
access to clean water and employ preventive chemotherapy.  Preventive chemotherapy with 
praziquantel given at 40mg/kg in school children living in schistosomiasis-endemic areas is 
recommended by WHO and has been given to millions of individuals [7]. Praziquantel 
penetrates the tegument of schistosomes and rapidly moves through the tissues causing 
tegument damage and worm paralysis. Work on the biochemical effects of praziquantel in 
mice has shown that tegumental damage in schistosomes can occur as early as 15 min after 
treatment and that worms take about 14–18 days to disintegrate [8]. Praziquantel is less 
effective on recent infections since it mainly attacks the mature schistosome worms but not 
the immature stages and as a result a second dose of praziquantel is recommended following 
the initial dose in order to kill the worms which were immature during the first treatment. 
Studies have suggested that a repeat dose of praziquantel, given 2 to 8 weeks after the first 
dose, can improve cure rates and reduce remaining intensity of infections in population-based 
programs [9]. 
Praziquantel has gained widespread usage because it is easy to administer, safe, well 
tolerated, cheap, can reverse schistosome-related morbidity and is highly effective against the 
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six schistosome species that infect humans [10]. Improving the health of school children has 
emerged as a policy priority in developing countries and recent control efforts have focussed 
their attention on mass treatment campaigns using praziquantel in school children with 
numerous mass drug administration programs currently being undertaken in countries such as 
Uganda, Sierra Leone, Burkina Faso and Mali[11, 12, 13]. Scaling up of mass drug 
administration was proposed in the WHO’s strategic plan of 2012 and by 2020, the global 
health community aims to have controlled and eliminated human helminthiases [14].  
Targeting treatment in children makes a significant impact on the development of pathology 
since severe clinical forms of schistosomiasis infection may take many years to develop[15]. 
Several studies have shown that mass drug administration using praziquantel drastically 
reduces morbidity and transmission of schistosomiasis with a satisfactory egg reduction rate 
[16, 17] especially in low-to-moderate transmission areas where the risk of reinfection is 
generally low. The WHO recommends expression of treatment outcome in terms of egg 
reduction rate calculated as the difference of the arithmetic mean egg counts between pre- 
and post-treatment samples. In this study arithmetic mean egg counts were used to calculate 
the intensity of infection and egg reduction rate [16]. 
Cure rates for praziquantel are variable ranging from 60 to 95% [18, 19] with high cure and 
egg reduction rates having been reported in Côte d'Ivoire [20] and South Africa [21]. 
However, concerns about praziquantel efficacy have been raised with a few reports on low 
cure rates recorded in Senegal [22] and Ghana [23]. The discrepancies in efficacy could be 
linked to drug resistance, presence of pre-patent infections existing at the time of treatment in 
high transmission areas and the inadequacy of single dose of 40 mg/kg under conditions of 
extremely high intensity of S. haematobium infection [24]. 
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The long-term effects of mass drug administration on infection dynamics are not yet fully 
understood even though the impact of S. haematobium infection and morbidity in affected 
individuals is unequivocal. As such the current longitudinal study aimed to investigate the 
effects of annual treatments with praziquantel over a period of two years on the infection 
intensity, prevalence, reinfection rates, antibody profiles and inflammation markers in school 
children attending Bandanyenje primary school so as to add to the body of knowledge on the 
epidemiology and effects of schistosomiasis treatment in Manicaland. Information on the 
efficacy of mass drug administration and praziquantel can assist in evaluating policies and 
strategies that guide schistosomiasis control activities in the district. 
2.3 Reinfection 
Although praziquantel is efficient in eradicating active infection, reinfection occurs rapidly 
after a single mass drug administration and is a challenge in communities where it is 
unavoidable to get in contact with water infested with snails carrying the S. haematobium 
larvae. Concerns have been raised regards mass drug administration which include failure in 
treating some individuals, potential for resistance to develop and spread throughout the 
population [22, 23]. The rate and intensity of post-praziquantel chemotherapy reinfection 
varies between schistosome species, socio-demography, and level of schistosomiasis 
prevalence [25]. 
Children are more rapidly reinfected and at higher rates than older children and adults [26]. 
These higher rates of reinfection are in part related to higher levels of water contact by 
children, a feature unique to most endemic settings. As such that there is a need for improved 
early diagnosis and treatment of children in endemic areas who seem to lack developed 
immune systems against the disease [27]. Control of reinfection requires repeated mass 
treatment where the intensity of application and the interval between treatments are 
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dependent on the reproductive life-expectancy of the adult worm. In the current study 
treatment was repeated annually for 2 years in order to control reinfection. Since the entire 
population does not get reinfected at the same rate, it is possible that host factors may play a 
dominant role in determining resistance or susceptibility to reinfection with schistosomes. In 
this study we analysed the general Schistosoma-specific antibodies and inflammation markers 
and tried to identify the host immune factors that either predispose or protect the host from 
infection or reinfection. 
2.4 S. haematobium-induced pathology: Haematuria 
The WHO recommends determination of haematuria and egg based counts for effectively 
identifying communities with high, moderate or low risk for schistosomiasis. Studies have 
shown that prevalence of S. haematobium-induced pathology like haematuria can be reduced 
after praziquantel treatment [28, 29]. Effectiveness of praziquantel treatment has been 
assessed through its effect on the intensity and prevalence of S. haematobium infection and 
morbidity. Although there is an association between prevalence, intensity of infection and the 
presence or severity of morbidity, the correlation is imperfect, and there is a need to monitor 
these parameters especially in individuals on repeated mass treatments. The information 
obtained can be useful in evaluating the effect of infection and repeated treatments on 
Schistosoma-induced morbidities. 
Studies of morbidity reduction related to drug treatment have had some conflicting results 
which may be a reflection of differences in follow-up after treatment, methods used to 
measure morbidities, the Schistosoma species, the presence of co-infections (especially 
malaria), the type of population and the region, the initial prevalence of infection, the 
incidence of reinfection, and other factors [29,30]. 
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2.5 Immune responses and Chemotherapy 
Studies on the effects of chemotherapy on helminths indicate that the drug treatment can 
facilitate the development of resistance to re-infection. The action of the praziquantel results 
in a transient increase in antigens from damaged worms, resulting in an increase in the 
specific immune responses (both humoral and cellular) which assist in killing the damaged 
and paralysed worms. In the absence of reinfection, the levels of both worm and egg antigen 
would eventually decline. Chemotherapy-induced changes in responses to infection have 
been reported on a number of occasions [31, 32], with frequent treatments thought to enhance 
the development of protective immune responses. Lympho-proliferative responses have been 
shown to increase following chemotherapy in S.mansoni and S. haematobium infected 
communities [32]. Grogan et al. (1996) [33] reported that levels of anti-soluble egg antigen 
(SEA) IgE, antiwhole worm homogenate (WWH) IgE and IgG4 increased following 
treatment whilst a study in Sudan reported a significant increase in anti-WWH IgG1 and 
IgG4 following treatment of schistosomiasis [34]. 
Studies of the effects of chemotherapy on other helminths indicate that the drug treatment can 
facilitate the development of resistance to reinfection through enhanced production of 
protective antibodies and decline in blocking antibodies. Key information on the humoral 
immune status of individuals can be determined routinely by measuring total 
immunoglobulin levels. Studies have realized the association between total immunoglobulins 
in chronic diseases associated with inflammation such as diabetes [35, 36]. Very little has 
been done on the association between the levels of total immunoglobulins and 
schistosomiasis, which is also a chronic disease that is also associated with inflammation. 
Indeed treatment of schistosomiasis has shown to be associated with subsequent changes in 
humoral and cell immune responses though focus has been mainly on Schistosoma- specific 
antibodies. Analysing such changes in the context of both total and specific antibodies will 
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assist in interpreting the differences that occur in children living in endemic areas as well as 
improving current understanding of the development of acquired immunity to schistosome 
infections and vaccine development. In order to establish the relationships between total 
serum immunoglobulins and S. haematobium-specific antibodies and to better understand 
their turnover after praziquantel treatment, we quantitatively measured the total 
immunoglobulins and specific antibody profiles in school children before and after treatment. 
2.6 Acute Phase Proteins and IL-6 
Chronic inflammation subsequent to infection with S. haematobium appears to be the major 
source of burden in individuals with shistosomiasis. There is an increased risk of cases of 
direct and indirect morbidities such as anaemia, growth deficiencies, physical fatigue and 
diminished cognitive development as a result of stimulation of tissue- destructive 
inflammatory and granulomatous reactions from S. haematobium infection [37, 38]. In the 
control of parasitic diseases, immune responses and consequently the inflammatory processes 
are meant to eliminate the harmful agent and restrict tissue damage but in some situations it 
may end up triggering pathological repercussions that can also effect injury and illness itself. 
In some instances inflammation can persevere even after the harmful agent has been 
eliminated, giving rise to chronic inflammation [39].Chronic inflammation can be seen as a 
continuous series of distinct and consistent inflammatory stimuli which results in increased 
serum concentrations of acute phase proteins and proinflammatory cytokines [40] which seek 
to inhibit the infection [41]. 
Induction of inflammatory reactions has been found to occur as a result of Schistosoma 
infection.The extent of inflammatory tissue damage as well as diagnostic and prognostic 
information in some human diseases can be resolved by measurement of acute phase proteins 
[42]. However there is inadequate information regarding the use of acute phase proteins in 
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parasitic infections like schistosomiasis in humans. This is unusual considering the fact that 
parasitic infections elicit considerable inflammation. Although perpetual and continuous 
inflammation is presumed to be a hallmark of schistosomiasis, very few studies have actually 
examined the acute phase proteins simultaneously with the proinflammatory cytokine IL-6 in 
S. haematobium infections. Acute phase proteins are released as a result of the action of 
cytokines such as IL-1, IL-6, and TNF-α produced by T-lymphocytes, macrophages, 
monocytes, endothelial cells, and fibroblasts [43] at the site of inflammatory lesions. 
Although it is evident that a number of proinflammatory and anti-inflammatory cytokines are 
involved in the inflammatory response, available data indicates that IL-6 is the supreme 
stimulator [44]. In endemic areas there is constant exposure of worms and egg burden which 
constantly triggers inflammation which can result in acute phase proteins production being 
chronic. 
There is unequivocal evidence that praziquantel treatment minimizes worm burden thereby 
reducing the amount of deposited eggs culminating in an overall decline in inflammation 
related to the immunopathological reactions to the eggs. Therefore, praziquantel should be 
able to reduce chronic inflammation especially if administered regularly as in mass treatment 
campaigns. Knowledge of inflammation markers is necessary in assessing and identifying 
children who are likely to develop chronic pathologies later on in life. Identifying such 
individuals at an early stage who are vulnerable to inflammation allows better prognosis and 
prevents the use of invasive, costly and time consuming procedures to determine those 
suffering from pathological complications of chronic inflammation conditions. The ultimate 
goal of disease monitoring is to identify individuals at risk in order to treat earlier.  
 We initially determined S. haematobium infection status then measured four different types 
of acute phase proteins that have not been commonly measured in other studies and IL-6 at 
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baseline to assess inflammation in both S. haematobium infected and S. haematobium 
uninfected school children. Most studies have investigated one acute phase protein at a time 
and not much information regards the overall effect of S. haematobium infection on 
inflammation has been realised as the acute phase proteins have different half-lives hence the 
need to use four different markers in our study. Secondly we established whether repeated 
rounds of praziquantel treatment for 2years results in changes in the acute phase proteins and 
IL-6. Knowledge on inflammation markers and how they respond to treatment can assist in 
development of therapeutic interventions that may help alleviate or relive development of 
chronic inflammation and the associated morbidities. 
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CHAPTER 3: GENERAL METHODOLOGY 
 
This chapter gave a detailed account of the steps to be taken in investigating the research 
objectives in this study. It included information on the study design, study area and 
population. The criteria used in the inclusion and exclusion of participants in the study were 
covered. In addition it covered specimen collection, specimen processing, data analysis and 
ethical considerations. 
3.1 Study area and population 
 
The study was carried out in Bandanyenje Primary School located in a schistosomiasis-
endemic setting in the Manicaland Province of Zimbabwe. It is located approximately 217 
Km south of Harare with latitude and longitude of 7°1′N 38°35′E. In Bandanyenje, safe water 
and sanitation coverage are poor. Villagers depend on perennial rivers as their water source 
thus exposing the majority of their population to infection. The rivers that provide habitats for 
Schistosoma intermediate host snails lead to moderate to high transmission rates of 
Schistosoma parasites. Bathing, swimming, fetching water, and laundry are the main water 
contact activities for school children in these areas. The area is endemic to S. haematobium 
with a provincial overall schistosomiasis prevalence of 23.8% [1]. The study population 
included a random sample of 212 (105 boys and 107 girls) aged between 7–13 years who 
were attending Bandanyenje primary school. 
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Figure 3.1: Map showing location of study site in Zimbabwe 
 
3.2 Study design 
 
This study design is a “before and after experiment “. It is a longitudinal survey conducted 
before and after treatment with praziquantel. All the children in the study were treated 
regardless of infection status as the study was part of the National Schistosomiasis Control 
programme, were all children were required to take part unless their guardians declined. The 
following parameters were assessed. 
Prevalence and intensity: A urine and stool examination was conducted in all children 
selected for the study at baseline, at 6 weeks and 2years after. A child was considered 
infected by S. haematobium if at least one egg was found in a urine sample during 
32 
 
microscopic examination [2]. Egg reduction rate (ERR) calculated as the difference of the 
arithmetic mean egg counts were measured in pre- and post-treatment samples [3]. 
Reinfection: This involved microscopic evaluation of urine at baseline, 6 weeks and 2 years 
following treatment. Re-infection cases were defined as those that were positive for 
schistosomiasis at baseline and became negative on the second examination at 6 weeks 
reverting to positive 2 years later [4]. 
Praziquantel treatment: At baseline, praziquantel (40 mg/kg) [5] was administered to all 
children selected, regardless of infection status. At 6 weeks and 2 years after treatment, urine 
samples were collected from each child to assess the efficacy of the treatment. Any individual 
was considered cured if no egg was found in the urine sample examined.  
Antibody profiles: Total and Schistosoma-specific antibody levels were measured at baseline 
and 2 years after repeated rounds of annual treatment with praziquantel. 
Inflammation markers: Acute phase proteins: procalcitonin, tissue plasminogen activator, 
ferritin and fibrinogen were measured at baseline and 2 years after repeated rounds of annual 
treatment with praziquantel. 
3.3 Inclusion and exclusion criteria 
3.3.1 Inclusion criteria 
In order to be included in the study, participants had to meet the following criteria: 1) be aged 
7–13 years at recruitment, 2) had provided at least two urine and one stool sample on three 
consecutive days at each follow-up time point for the duration of the two year study period, 
3) be negative for intestinal soil transmitted helminths and S. mansoni, 4) have successfully 
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taken the praziquantel tablets prescribed to them and, 6) parents/guardians had given consent 
for their children to be included in the study.  
3.3.2 Exclusion criteria 
Children were excluded from the study if they were outside the 7-13 age range, did not 
provide the required stool and urine samples, positive for intestinal soil transmitted helminths 
and S. mansoni and if their parents/guardians did not consent. Those who failed to 
successfully take the praziquantel tablets were also excluded from the study. 
3.4 Sample collection and examination 
3.4.1 Urine examination and collection 
S. haematobium was determined using urine specimens collected from each child on three 
consecutive days. The urine samples were processed for urinary schistosomiasis using the 
filtration technique following Mott et al., 1982 [6]. Generally, specimens were collected 
around noon (between approximately 1000hrs and 1300hrs), time for best results. The 
samples were transported to the laboratory for microscopic examination of S. haematobium 
eggs on the same day using the urine filtration method and microscopy. Briefly, 10 ml of 
well-mixed urine was aspirated and slowly forced through a filter membrane. The filter was 
removed and placed on a slide, covered with a cover slip and examined under a light 
microscope. The number of eggs on the entire filter was counted and recorded as the number 
of eggs/10 ml urine. The same procedure of urine examination was carried out at baseline, 6 
weeks and 2 years post treatment. A sample with the number of eggs greater than zero in 
10 ml of urine was classified as being positive S. haematobium infection. The prevalence was 
defined as the number of infected children with S.haematobium over the total number 
screened [4].  
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Intensity of S.haematobium infection was expressed as number of eggs per 10 ml (EP10ml) 
of urine. Infection intensities were classified into three categories: (1) light infections (<10 
EP10ml), (2) moderate infections (10EP10ml<x<50EP10ml and (3) heavy infections (≥50 
EP10ml). 
As a measure for Schistosoma-induced pathology, haematuria was determined in urine 
samples collected at baseline and 2 years following treatment with 40mg/kg praziquantel. A 
Combur-Test (Roche Diagnostics GmbH, Mannheim, Germany) reagent strip was used to 
detect the presence of blood in the urine. 
3.4.2 Stool collection and examination 
A single stool sample was collected from each child for microscopic examination on the same 
day to determine S.mansoni and soil transmitted helminthiasis (STH) infections following the 
Kato Katz technique as modified by Peters et al., (1980) [7]. Stool examination was carried 
out at baseline and all children who were positive S. mansoni and STH were excluded from 
the study. 
3.4.3 Blood collection and examination 
About 5mls of venous blood was collected from each participant before praziquantel 
treatment and at each post treatment survey. Serum was collected and used in the 
determination of total, Schistosoma- specific antibodies, acute phase proteins and IL-6. 
3.4.3.1 Determination of total antibody levels 
50ul 1x beads were added to a 96 well micro titer plate and washed 2x with the Bio-rad wash 
buffer. The standards, samples and controls were diluted (Bio-rad Antibody diluents) and 50 
ul added to the wells and incubated in the dark at room temperature with shaking at 850 rpm 
for 1 hour. After incubating the beads, samples, standards, blank, and controls the plate was 
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washed three times with 100ul wash buffer. 1x detection antibodies were added to the assay 
plate and incubated in the dark for 30min with shaking at 850rpm. The plate was washed 3x 
and Streptavidin –PE was added. The assay plate was incubated for 10 min at room 
temperature with shaking at 850rpm. The plate was washed 3x and the beads were re-
suspended for plate reading. The Bio-plex manager software was used for running the assay, 
data acquisition and analysis. 
3.4.3.2 Specific antibody determination 
A standard indirect ELISA was optimized and used to quantify the amount of antibodies 
IgG1, IgG4 and IgE produced directly against S.haematobium 13 antigen. The pre-treatment 
serum samples were the first to be analyzed followed by post treatment serum samples. The 
S. haematobium13 antigen was diluted with a 7.4 pH coating buffer after which 100ul of the 
diluted antigen was added to each well in a 96 well microtiter plate. The plates were covered 
with a parafilm and placed in the fridge at 4 degrees Celsius for 18 hours. The following day 
the plates were washed three times with Tris Buffer Saline at three minutes interval. Egg 
albumin solution was used to block the non-specific binding sites and the plates were allowed 
to shake for an hour. After an hour plates were washed three times again at three minutes 
interval. 
The serum samples were diluted with a dilution buffer. For IgG1, 25ul of the sample were 
added to 225ul of the dilution buffer and for IgG4, 10ul of the sample was added to 490ul of 
the dilution buffer. 100ul of the diluted samples was added to the microwells in duplicate.  
The other six microwells were reserved for positive, negative controls and blank in duplicate. 
The incubation period was 2 hours. After 2 hours the plates were removed from the shaker 
and washed for three times again. About 10ul of the antibody solution was added to 10ml of 
the diluents buffer. Eventually, 100ul of the mixture was added to the ELISA plate and 
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incubated for an hour at room temperature. The plates were washed for six times at this stage. 
About 100ul of the o- Phenylenediamine Dihydrochloride (OPD) substrate was added to each 
well containing horse reddish peroxidase enzyme and incubated for 30 minutes in the dark. 
The enzyme reaction was stopped with sulphuric acid and the readings were measured at 
450nm wavelength. 
3.4.3.3 IL-6 determination 
The analysis of IL-6 in the serum samples was done by sandwich ELISA. 100 ul of coating 
antibody was added into the wells of an ELISA plate. The plate was then covered with 
adhesive to prevent evaporation and incubated overnight at 4oC. After incubation the plate 
was turned over to remove the coating antibody and was washed thrice with the wash buffer. 
The plate was dried by blotting on a paper towel to remove residual wash solution.200ul of 
5% egg albumin was added to all the wells to block nonspecific binding sites. The plate was 
covered with adhesive tape and incubated for 1 hour at room temperature on a plate shaker. 
After incubation the plate was turned over to remove the coating antibody and was washed 
thrice with the wash buffer. The plate was dried by blotting on a paper towel to remove 
residual wash solution. 100 ul of the sample was added into wells in duplicate. The plate was 
covered with adhesive tape and incubated for 2 hours at room temperature on a plate shaker. 
After incubation the plate was turned over to remove the sample and was washed thrice with 
the wash buffer. The plate was dried by blotting on a paper towel to remove residual wash 
solution.100 ul of biotin conjugated antibody was added into the wells. The plate was covered 
with adhesive tape and incubated for 1 hour at room temperature on a plate shaker. After 
incubation the plate was turned over to remove the detection antibody and was washed thrice 
with the wash buffer. The plate was dried by blotting on a paper towel to remove residual 
wash solution.100 ul of Horse Radish Peroxidase (HRP) antibody was added into the wells. 
The plate was covered with adhesive tape and incubated for 1 hour at room temperature on a 
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plate shaker. After incubation the plate was turned over to remove the HRP conjugate 
antibody and was washed six times with the wash buffer. The washing was done thoroughly 
to remove all unbound HRP conjugate antibodies. The plate was dried by blotting on a paper 
towel to remove residual wash solution.100 ul of OPD substrate was added to the plate and 
incubated for 20 minutes in the dark. The plate was covered with a foil paper to prevent light 
from interrupting with the reaction. After incubation 20ul of the stop solution was then added 
to each well. The plates OD was read at dual wavelength for cytokine analysis (405nm and 
630nm) in an ELISA plate reader. 
 
3.4.3.4 Acute Phase Proteins determination 
There has been an interest in using more than one inflammatory biomarker in various 
parasitic diseases due to the varying half lives of the biomarkers. Parasitic infections have 
been found to be associated with increased serum concentrations of procalcitonin and ferritin. 
To the best of our knowledge, procalcitonin, ferritin, tissue plasminogen activator and 
fibrinogen have not been investigated in children residing in schistosomiasis endemic areas. 
Serum levels of ferritin, fibrinogen, tissue plasminogen activator and procalcitonin, were 
determined in the school children  by  the magnetic bead–based immuno-assays using the 
Bio-Plex Pro™ human acute phase 4-plex immunoassay complete commercial kits. 25ul 1x 
beads were added to a 96 well micro titer plate and vacuum filtration was carried out. The 
standards, samples and controls were diluted and 50 ul added to the wells and incubated in 
the dark at room temperature with shaking at 850 rpm for 1 hour. After incubating the beads, 
samples, standards, blank, and controls vacuum filtration was done and the plate was washed 
three times with 100ul wash buffer. 25ul of 1x detection antibodies were added to the assay 
plate and incubated in the dark for 30min with shaking at 850rpm. The plate was washed 3x 
and Streptavidin –PE was added. The assay plate was incubated for 10 min at room 
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temperature with shaking at 850rpm. Vacuum filtration was done and the plate was washed 
3x and the beads were re-suspended in assay buffer prior to reading the plate. The Bio-plex 
manager software was used for running the assay, data acquisition and analysis. 
3.5 Statistical analysis 
Data was entered into the computer using Microsoft Excel spread sheet and exported to SPSS 
for windows version 16.0 (SPSS Inc., Chicago, Illinois, USA). The Pearson chi-square test 
was used to determine the association between the prevalence of S. haematobium infections, 
arithmetic egg counts and age orgender. Student t-test was used to compare differences in the 
prevalence and intensity of infection (eggs/10ml urine) before and after treatment. A value of 
p<0.05 was considered as statistically significant.  
To determine if there was a significant difference between pre-and post-treatment of the total 
immunoglobulin as well as the specific antibody profiles a comparison of means using a 
paired t-test was conducted. The hypothesis that there were no differences between pre-
treatment and 2 years post treatment antibody profiles was tested. P value was set at p<0.05. 
Levels of serum levels of ferritin, fibrinogen, tissue plasminogen activator, procalcitonin and 
IL-6 at baseline and 2 years post-treatment were compared using student t test to determine 
the effect of praziquantel treatment on acute phase proteins and IL-6. The Mann–Whitney 
non parametric test was used to determine the effect of S. haematobium infection on the 
levels of ferritin, fibrinogen, tissue plasminogen activator, procalcitonin and IL-6. A value of 
p < 0.05 was considered to indicate a significant difference in statistical analyses. 
3.6 Ethical Approval 
Ethical approval and clearance of the study was obtained from the Biomedical Research 
Ethics Committee (BREC – UKZN), approval code, BE 467/16 (appendice 7.2) as well as the 
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Medical Research Council of Zimbabwe (MRCZ), approval code, MRCZ/A/1958 (appendice 
7.1).  The aims, objectives and procedures of the study were explained to the 
parents/guardians of the recruited children in the local language (Shona), when they were 
invited to participate. Written informed consent was obtained from all the guardians of the 
school children in Shona (appendice 7.4) and English (appendice 7.5). Participation was 
voluntary and the parents/guardians had the right to withdraw their child/children at any time 
point from the study. Treatment was administered by trained medical personnel and the 
children were closely monitored. Written consent to transport participants’ specimens to 
UKZN for antibody profiles and acute phase protein determination was also obtained from 
parents/guardians (appendice 7.3). 
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CHAPTER 4: Benefits of Annual Chemotherapeutic Control of Schistosomiasis on the 
Development of protective Immunity 
 
The first three chapters  presented the background information in the area of study as well as 
the purpose carrying out this research (Chapter 1) and the current and previous findings from 
other researchers in the field (Chapter 2). In the third chapter, a comprehensive account of 
the investigations to be carried out in order to meet all the objectives was outlined.  
Several studies have investigated the efficacy of praziquantel in treatment of schistosomiasis, 
however scaling of repeated mass treatment campaigns has recently been adopted in 
Zimbabwe especially in the area under study. Reinfection with S. haematobium is common in 
individuals given a single dose, more so in moderate to high transmission areas. Children 
residing in the same area and exposed to the same Schistosoma-infested waters are infected 
and reinfected with S. haematobium differently which points towards, though not limited to, 
host immunity and genetic factors. We established the relationship between the humoral 
responses and the infection status and determined whether protective or blocking antibodies 
are responsible for the observed differences. The impact of repeated treatment on 
schistosomiasis prevalence, reinfection rates and more importantly on protective and 
blocking antibodies was determined. 
This chapter focused on the first two objectives and combined the effect of repeated mass 
treatment with praziquantel on prevalence, intensity of infection and reinfection rates. It then  
analysed the antibody profiles in S. haematobium infected and uninfected individuals in order 
to determine if any antibody isotypes protect or predispose an individual to infection as well 
as to ascertained the effect of repeated treatment on the antibody profiles.  
This chapter was submitted in the format of the target journal. 
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4.1: Abstract 
Background: Schistosomiasis is a devastating parasitic disease. The mainstay of 
schistosomiasis control is by praziquantel treatment. The study aimed to determine benefits 
of annual chemotherapy of schistosomiasis on development of protective immunity in school 
children in a selected endemic rural area in Zimbabwe. 
Methods: Urine specimens from 212 school children (7-13 years) were collected and 
examined to determine prevalence, intensity and reinfection of S.haematobium at baseline, 6 
weeks and 2 years following praziquantel treatment. Blood samples from the participants 
were assayed for total and S. haematobium (Sh13)-specific antibodies before and 2 years after 
annual treatment. 
Results: Annual treatment reduced the prevalence of S. haematobium infection (p<0.05) from 
23.1% at baseline to 0.47 % after 2 years. Overall cure rate was 97.8 %. Intensity of infection 
declined (p<0.05) from 15.9 eggs/10ml urine at baseline to 2 eggs/10ml urine. After two 
years, overall rate of reinfection was 0.96 %. At baseline, total IgG4 was higher in S. 
haematobium-infected children (p=0.042), while all other immunoglobulins were within 
normal ranges. There was an increase in total IgG2 (p=0.044) levels and a decrease in total 
IgG4 (p=0.031) levels 2 years post-treatment; and no significant changes in other total 
immunoglobulins. Schistosoma-positive children at baseline showed an increase in anti-
S.haematobium 13 IgG1 (p=0.005) and a decrease in S. haematobium 13 IgG4 levels 
(p=0.012) following treatment. 
Conclusion: Annual praziquantel treatment delivered to school children over 2 years 
significantly reduces prevalence, intensity of infection and reinfection of S. haematobium 
infection. Treatment was also observed to cause a reduction in schistosome-specific blocking 
IgG4 and an increase in Schistosoma-specific protecting IgG1. 
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4.2 Introduction 
Schistosomiasis is a devastating neglected tropical disease (NTD) that begins when infective 
cercariae from freshwater snails pierce the skin as a result of exposure to infested water [1]. 
Such a scenario is typical in resource limited settings with poor sewage disposal and 
inadequate supply of clean water. It is estimated that over 250 million people are infected 
with schistosomiasis, worldwide. Approximately 93% of the infected people reside in sub-
Saharan Africa [2], where school children carry the heaviest burden and account for the 
highest prevalence and intensity of schistosome infections [3]. Children are mainly affected 
because of their higher rates of water related activities, immunological status and anatomical 
vasculature [4, 5]. Such young children suffer from haematuria, dysuria, nutritional 
deficiencies, anaemia, growth retardation, decreased physical performance and impaired 
memory and cognition as a result of extreme schistosome infections [6, 7]. 
The Ministry of Health and Child Care in Zimbabwe included schistosomiasis in the 2009-
2013 National Health Strategy in 2009 underlining the importance and the urgent need to 
control the disease. A nationwide schistosomiasis survey was conducted in Zimbabwe and 
the overall prevalence of S. haematobium was reported as 18.0% while that of S. mansoni 
was 7.2%. Manicaland region, where this study was conducted has a moderate burden of the 
parasitic disease at 23.8% prevalence of schistosomiasis [8]. 
Chemotherapeutic control using praziquantel is aimed particularly at school-age children 
living in schistosomiasis-endemic areas. The treatment and control measure for 
schistosomiasis has been recommended by the World Health Organization (WHO) [9] as an 
interim available control strategy, since no vaccines are as yet available. Praziquantel is a 
pyrazino-quinoline derivative and has gained widespread usage because it is easy to 
administer, safe, well tolerated, cheap, can reverse schistosome-related morbidity and is 
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highly effective against the six schistosome species that infect humans [10, 11].  Mass drug 
administration using the anti-helminthic drug praziquantel has been the major focus of recent 
control efforts [12], with the principal aim of reducing morbidity and clearing sources of 
recontaminating the environment. Scaling up of mass drug administration has been proposed 
in the WHO’s strategic plan of 2012 as a way of managing schistosomiasis morbidity by 
2020 [13]. Schools have been targeted for mass treatments because of the increased benefits 
of reducing infection burdens in children compared to adults and the simplicity of providing 
treatment [14]. Many studies have shown that praziquantel drastically reduces morbidity and 
transmission of schistosomiasis especially in low-to-moderate transmission areas where the 
risk of reinfection is generally low [15 - 17] despite a few reports of treatment failures [18, 
19]. 
Although praziquantel is efficient in mitigating or eradicating active infection, not everyone 
is cured. As a result, rapid reinfections have been reported and remain a challenge in 
communities where it is unavoidable to get in contact with water infested with snails carrying 
the S. haematobium cercariae [20].Treatment using praziquantel must be repeatedly 
administered for an indefinite time period in order to maintain low reinfection levels [21], 
however the long-term effects on infection dynamic and immune status are not yet fully 
understood. In our current study, repeated annual rounds of praziquantel were administered to 
children attending Bandanyenje primary school. Although the overall prevalence and 
distribution of schistosomiasis have been reported in the province, less emphasis has been 
given to the effect of repeated rounds of praziquantel and the subsequent prevalence, intensity 
of infection and re-infection rates in Bandanyenje. Information on the efficacy of 
praziquantel and the infection rates may help in evaluating policies and strategies that guide 
schistosomiasis control activities in the district. Thus, we assessed the effect of annual 
treatment with praziquantel over 2 years on the prevalence and reinfection rates in school 
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children attending Bandanyenje primary school in Manicaland province of Zimbabwe. The 
intensity of Schistosoma infection, using the major symptom, haematuria, as an indicator was 
also evaluated.  
Several studies have reported the chemotherapy-induced changes in responses to 
Schistosomal infection [13, 22, 23]. Frequent treatments are thought to enhance the 
development of protective immune responses. Studies of the effects of chemotherapy on 
other helminths indicate that the drug treatment can facilitate the development of resistance to 
reinfection through enhanced production of protective antibodies and decline in blocking 
antibodies. Key information on the humoral immune status of individuals can be determined 
routinely by measuring total immunoglobulin levels. Several studies have realized the 
association between total immunoglobulins in chronic diseases associated with inflammation 
such as diabetes [24, 25]. Very little has been done on the association between the levels of 
total immunoglobulins and schistosomiasis, which is also a chronic disease that is associated 
with inflammation. Indeed treatment of schistosomiasis has shown to be associated with 
subsequent changes in humoral and cellular immune responses although focus has been 
mainly on Schistosoma- specific antibodies [22]. Analysis of such changes in the context of 
both total and Schistosoma-specific antibodies will assist in interpreting the differences that 
occur in children living in endemic areas as well as improving current understanding of the 
development of acquired immunity to schistosome infections and vaccine development. In 
order to establish the relationships between total serum immunoglobulins and 
S.haematobium-specific antibodies and to better understand their turnover after praziquantel 
treatment we quantitatively measured the total immunoglobulins and specific antibody 
profiles in school children before and after two annual rounds of treatment using praziqunatel 
inorder to determine benefits of annual chemotherapy of schistosomiasis on development of 
protective immunity in the school children. 
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4.3 Methodology 
Study area and population 
The study was carried out in Bandanyenje Primary School located in a schistosomiasis-
endemic area in the Manicaland Province of Zimbabwe. The school is approximately 217 km 
South-East of Harare with latitude and longitude of 7°1′N 38°35′E. Villagers living in 
Bandanyenje community depend on perennial rivers as their water source thus indicating an 
increased likely exposure of the majority of their population to infection. The study 
population included a random sample of 212 (105 boys and 107 girls) aged between 7–13 
years who had provided at least two urine and one stool sample on three consecutive days at 
each follow-up time point for the duration of the two year study period. All school children 
who successfully took praziquantel tablets prescribed to them were included in the study and 
those school children outside the 7-13 age range, did not provide the required stool and urine 
samples and failed to successfully take the praziquantel tablets were excluded from the study. 
Parasitology and blood sampling 
A school-based longitudinal intervention study was conducted and involved examination and 
treatment of the study population at baseline, 6 weeks and at 2 year follow up surveys. Stool 
and urine samples were collected at baseline and at follow up, for each examination time-
point over three consecutive days. The urine samples were processed for urinary 
schistosomiasis using the filtration technique following Mott et al., 1982 [26] methods. The 
stool samples were processed following the Kato Katz technique by Peters et al., (1980) [27]. 
A sample with the number of eggs greater than zero in 10 ml of urine was classified as being 
S. haematobium-positive. Those found to be infected with S. mansoni were excluded from the 
study. The prevalence was defined as the number of infected children with S. haematobium 
over the total number screened. Intensity of S.haematobium infection was expressed as 
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number of eggs per 10 ml (ep10ml) of urine. Infection intensities were classified into three 
categories: (1) light infections (<10 ep10ml), (2) moderate infections 
(10ep10ml<x<50ep10ml and (3) heavy infections (≥50 ep10ml). Blood samples were 
obtained from the children, the serum separated and used to determine total immunoglobulins 
and antibody profiles against S. haematobium13. 
Determination of total antibody profiles 
About 50μl 1x beads were added to a 96 well micro titer plate and washed 2x with the Bio-
Rad wash buffer. The standards, samples and controls were diluted (Bio-Rad Antibody 
diluent and 50 μl added to the wells and incubated in the dark at room temperature with 
shaking at 850 rpm for 1 hour. After incubating the beads, samples, standards, blank, and 
controls the plate was washed three times with 100μl wash buffer. 1x detection antibodies 
were added to the assay plate and incubated in the dark for 30min with shaking at 850rpm. 
The plate was washed 3x and Streptavidin –PE was added. The assay plate was incubated for 
10 min at room temperature with shaking at 850rpm. The plate was washed 3x and the beads 
were re-suspended for plate reading. The Bio-plex manager software was used running the 
assay, data acquisition and analysis. 
Determination of S. haematobium (Sh13) specific antibodies 
A standard indirect ELISA was optimized and used to quantify the amount of antibodies 
IgG1, IgG4 and IgE produced directly against S.haematobium 13 antigen. Both pre- and post 
– treatment samples were analyzed followed on the same plate. Briefly, the plates were 
coated with S. haematobium13 antigen at 5ng/ml over night at 4oC. Diluted serum was added 
at 1:10 for IgG4, 1:50 for IgG1 and IgE, dilutions. Monoclonal anti-human IgG conjugated to 
peroxidase was used to detect the presence of anti-S. haematobium 13 IgG1, IgG4 and IgE 
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antibodies.Six microwells were reserved for positive, negative controls and background blank 
containing myelin basic protein (MBP) in duplicate. This was due to the S.haematobium 13 
suspension contain MBP. About 100 μl of the o- Phenylenediamine Dihydrochloride (OPD) 
substrate was added to each well containing horse reddish peroxidase (HRP) enzyme and 
incubated for 30 minutes in the dark. The enzyme reaction was stopped with sulphuric acid 
and the absorbance was read at 450nm with 630nm as reference wavelength. 
Haematuria 
As a measure for Schistosoma-induced pathology, haematuria was determined in urine 
samples collected at baseline and 2 years following treatment with 40mg/kg praziquantel. A 
Combur-Test (Roche Diagnostics GmbH, Mannheim, Germany) reagent strip was used to 
detect the presence of blood in the urine. 
Treatment 
Treatment was carried out by qualified health teams of trained nurses and medical officers as 
part of the treatment campaign. All school children were treated with a single dose of 
40mg/kg praziquantel at baseline, and thereafter without considering the infection status after 
1 and 2 years. 
Statistical analysis 
Data was entered into the computer using Microsoft Excel spread sheet and exported to SPSS 
for windows version 16.0 (SPSS Inc., Chicago, Illinois, USA). The Pearson chi-square test 
was used to determine the association between the prevalence of infections, arithmetic egg 
counts with age or gender. Student t-test was used to compare differences in the prevalence 
and intensity of infection (eggs/10ml urine) before and after praziquantel treatment. A value 
of p<0.05 was considered as statistically significant. To determine if there was a significant 
difference between pre-and post-treatment of the total immunoglobulin as well as the specific 
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antibody profiles a comparison of means using a paired t-test was conducted. The hypothesis 
that there were no differences between pre-treatment and 2 years post treatment antibody 
profiles was tested. P value set at p<0.05.  
Ethical Approval 
Ethical approval and clearance of the study was obtained from the Medical Research Council 
of Zimbabwe (approval code, MRCZ/A 1958) and the Biomedical Research Ethics 
Committee (approval code, BE467/16) of UKZN. The aims, objectives and procedures of the 
study were explained to the parents/guardians of the recruited children in the local language 
(Shona), when they were invited to participate. Written informed consent was obtained from 
all the guardians of the school children. Participation was voluntary and the parents/guardians 
had the right to withdraw their child/children at any time point from the study. Treatment was 
administered by trained medical personnel and the children were closely monitored. 
4.4 Results 
Baseline prevalence, intensity and reinfection 
Of the 233 school children from Bandanyenje primary school who volunteered and provided 
urine and stool samples, S. mansoni was diagnosed in (9%) 21/233 and Soil Transmitted 
Helminths in 0.4% (1/233) and these children were not included in the study.  The remaining 
212 (105 boys and 107 girls) aged between 7-13 were recruited in the study and were 
successfully traced and re-examined at both follow-ups with complete sets of longitudinal 
parasitological data on S. haematobium infection. The overall pre-treatment prevalence of S. 
haematobium infection was 49(23.1 %) with 20(19%) boys and 29(27.2%) girls as 
determined using the urine filtration technique. The age group of 10-13 years as well as the 
girls had the highest prevalence 25.6% and 27.1 %, respectively. However the differences in 
infection status between age groups (χ2=0.158, p=0.691) and boys and girls (χ2=1.891, 
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p=0.169) were not significant (Table 4.1).The majority of infected children in the both age 
groups had light infections with more heavy infections being observed in the 7-9 age (10.5%) 
group than the 6.7% in the 10-13 age group. However the intensity of infection had no age 
group (χ2 =2.594, p=0.273) or sex-related pattern (χ2=0.297, p=0.862). The proportion of 
boys (10%) that had a heavy infection was greater than girls (6.9%) though not statistically 
significant (Table 4.1).  
There was an overall decline in S. haematobium prevalence from 23.1% at baseline to 0.47%  
at 6 weeks post-treatment and, 0.47% 2 years post-treatment  (p< 0.05). A total of 
211(99.5%) children were egg negative after treatment. The S. haematobium prevalence 
significantly decreased to 0.47% (p<0.05%) following 2 years of 3 annual rounds of 
praziquantel treatment. The overall Cure Rate (CR) was 97.8 % and Average Egg Mean 
Count (AEMC) was 15.9 egg/10ml urine at baseline and reduced to 2 egg/10ml urine 2 years 
post-treatment (Table 4.2). The study of reinfection involved the 211 children who were 
cured 6 weeks after the first praziquantel treatment. Of these S. haematobium negative, only 1 
boy (0.96%) contracted the infection 2 years after the 6 week treatment (Table 4.3). 
Haematuria 
Haematuria was detected in 32(15.1%) of the study participants of which 23(71.9%) were S. 
haematobium positive. The presence of S. haematobium eggs showed statistically significant 
association (χ2=20.38, p<0.05) with haematuria whilst there was no association between sex 
and haematuria (χ2=0.08, p=0.929). At 2 years post treatment, the extent of haematuria 
decreased from 100% to 0% (Table 4.4).  
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Total and S. haematobium specific antibodies 
Baseline levels of total IgG4 were significantly higher in S. haematobium positive compared 
to S. haematobium negative children (Figure 4.1). At 2 years after treatment, Serum IgG2 
increased and serum IgG4 decreased after treatment with praziquantel (p= 0.044 and 0.031, 
respectively). There were no significant changes in total serum IgG1, IgG3, IgM and IgA. 
Levels of S. haematobium IgG4 were significantly higher in S. haematobium positive when 
compared to S. haematobium negative (p<0.05). Following chemotherapy, significant 
decreases of S. haematobium IgG4 were observed. Specific S. haematobium-IgE levels before 
treatment were higher than the S. haematobium IgE levels though no significant changes were 
noted before and after treatment in both S. haematobium uninfected and infected children 
(Figure 4.2). The protective S.haematobium IgG1 increased significantly in S. haematobium 
infected children following treatment.  
4.5 Discussion 
At baseline survey, the prevalence of S. haematobium infection in the study area was 
observed to be low at 23.1% (Table 1) compared to other areas in Zimbabwe [8]. However, 
the prevalence was within the range of the average prevalence within the province 
(Manicaland, 23.8%) as determined by a nationwide survey that was conducted by Midzi et 
al (2014) [8]. The low prevalence of S. haematobium reported in this study could reflect the 
on-going control efforts in the area e.g. elimination of intermediate host snails and health 
education. Lately, constant awareness campaigns advocated during the annual mass drug 
administration exercise compounded by improved use of technology in rural areas have been 
part of efforts by the Ministry of Health to control schistosomiasis which had been neglected 
for a long time. This could have resulted in decreased contact with infested waters by 
children in the area. There is a need to maintain the low reinfection levels to prevent the 
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development of morbidities associated with high S. haematobium prevalence. The WHO 
guidelines recommend treatment with praziquantel once every 2 years in school children and 
high risk groups in communities with a schistosomiasis prevalence of 10% to 50%. The same 
groups should be given praziquantel once annually in communities where prevalence is 50% 
and above [28]. 
No association was found in the prevalence between boys (19%) and girls (27.1%), as well as 
between the different ages in this study (Table 4.1). This pattern of infection may be an 
indication of equal exposure of both genders and the ages examined in the study due to 
similar water contact activities. The findings are consistent with those found in a similar 
study in Ethiopia [29]. Other studies have shown either boys or girls to be significantly more 
affected. Differences in prevalence between boys and girls arise due to cultural, behavioural 
and social factors within an area with the most affected sex being the one having more water 
contact activities [30]. 
Infection intensity is a better indicator of morbidity associated with schistosomiasis than 
prevalence as it reflects the number of worms infecting the individual and it is also a more 
reliable marker of treatment success defined as the removal of egg-laying worms [31, 32].  
The baseline intensity of infection in this study was moderate (Table 4.2). The baseline 
infection intensity in our study indicated low infection levels comparable with findings from 
similar studies in Niger [16, 33]. 
Praziquantel remains the drug of choice for the treatment of schistosomiasis in spite of cases 
of low cure rates that have been reported in some areas [34]. We observed a significant 
decline in prevalence after the first dose at 6weeks exhibiting a satisfactory efficacy with 
praziquantel after the first dose (Table 4.2). In this study, our results demonstrated a 
significant impact of praziquantel in treatment of S. haematobium with cure rates of 97.8% 
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(p<0.05%) following 2 years of repeated annual rounds of praziquantel treatment. This is 
comparable to findings of similar studies that have reported a higher efficacy of praziquantel 
when administered as two or three treatments spaced at certain time intervals [14, 35]. The 
pronounced cure rates where 100% cure rate is achieved after 2 years could be due to the 
study period and the infection prevalence of the area as stipulated by the WHO, baseline 
infection intensity, brand of praziquantel used, geographical location/variation, repeated 
rounds with enhanced killing of schistosomula and the method of laboratory diagnosis 
employed, ie microscopy with egg determination does not rule out presence of the worm.  
Total prevalence of re-infection 2 years post-treatment was 0.96% (Table 4.3). It has been 
hypothesized that, after repeated rounds of infections and praziquantel chemotherapy, 
humans slowly acquire protective immunity to S. haematobium leading to partial resistance to 
re-infection [36]. Treatment with praziquantel boosts adult worm immunoglobulin E (IgE) 
antibodies which are associated with resistance to re-infection [17]. In contrast to our 
findings, other studies observed a rapid and high re-infection rate a few weeks following 
treatment especially in high transmission areas [37]. Presence of haematuria before treatment 
was correlated with the presence of S.haematobium eggs in urine. In response to treatment 
with single dose of praziquantel, haematuria fell from 100% to 0% at 2 years post- treatment 
(Table 4.4). Most studies measure haematuria within weeks or months whereas in our study 
haematuria was measured after two year following 3 annual rounds of treatment. Studies in 
Ghana and Kenya have also reported significant decreases in haematuria after praziquantel 
treatment [38, 39]. 
 
Our findings suggest that children at Bandanyenje primary school are at moderate risk of the 
morbidity caused by the moderate S. Haematobium prevalence according to WHO threshold 
and we recommend a biennial mass drug administration with praziquantel. There is mounting 
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evidence that anti-helminthic treatment using praziquantel not only transiently reduces 
infection, but also has longer term benefits in terms of morbidity control and the development 
of parasite-specific immune responses associated with resistance to reinfection [18, 40]. It is 
widely accepted that the changes in Schistosoma-specific immune response occur following 
treatment of schistosomiasis with praziquantel [7, 41]. Praziquantel penetrates the tegument 
of worm tissues and rapidly moves through damaging the tegument and causing paralysis of 
the worm [42]. The increase in antigens released from dying worms as a result of 
praziquantel induced-tegument damage is believed to trigger this change in both the cellular 
and humoral immune responses [43]. 
 
In this study following chemotherapy there were changes in both the total and S. 
haematobium-specific antibodies. There was a significant increase in total IgG2, total and S. 
haematobium-specific IgG1 and a significant decline in total and S. haematobium-specific 
IgG4 while there were no significant changes in all the other antibodies (Figure 4.1 and 
Figure 4.2). Studies done in individuals with chronic schistosomiasis have revealed elevated 
levels of total immunoglobulins [44]. We observed an increase in both the total and specific 
IgG1 which was maintained over the 2 years, which suggest that IgG1 could have been 
stimulated by antigens produced from the worms after chemotherapy. Khalife et al., (1989) 
[45] demonstrated the eosinophil-dependent killing of schistosomula as a result of IgG1. This 
could explain the significant increase of IgG1 following treatment with praziquantel and the 
significant clearance of infection at 6 weeks and thereafter 2 years later. The release of sub-
surface antigens and a decline in egg counts following treatment result in stimulation of IgG1 
production.  A similar increase in specific IgG1 following chemotherapy was noted by 
Mutapi et al (1998) [46]. They observed an increase in IgG1 following treatment with 
praziquantel, which they attributed to a switch from IgA specific antibodies to IgG1 response 
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that occurs in children. The potential mechanism for this switch is not fully understood, but it 
is believed that changes in cytokine levels in response to antigen release from damaged 
parasites may cause this isotype switch from IgA to IgG1 [23]. The switch occurs naturally as 
worms die but takes a long time as a result of life span of schistosomes. The switch is 
accelerated by the praziquantel treatment which actually causes partial protection to 
reinfection as seen by the 0.96 % reinfection rate 2 years post treatment noted in this study. 
Studies have demonstrated the protective role played by IgE, which surprisingly in this study 
showed no significant change in both the infected and non-infected group at baseline. 
Following treatment there were no significant changes (p<0.05) in IgE in both S. 
haematobium infected and uninfected (Figure 4.1), though the levels remained higher than 
blocking IgG4 levels that decreased significantly following chemotherapy. Similar trends 
though in S. mansoni were observed by Walter et al., (2006) [47]. They demonstrated that 
following treatment, adult worm-specific IgG4 levels decreased, while worm-specific IgE are 
maintained at pre-treatment levels or increases even in children, who more readily become 
reinfected, treatment is less likely to increase the IgE/IgG4 ratio. There is need therefore to 
carry out further studies especially taking into account cytokine levels which are key to 
facilitating the production of both the total and S. haematobium-specific antibodies. 
In our study S. haematobium uninfected children had significantly lower levels (p<0.05) of 
the blocking antibody IgG4 at baseline than the infected children, this was observed for both 
total and S. haematobium-specific IgG4 (Figure 4.1 and Figure 4.2). Blocking antibodies 
like IgG4 which have been observed to develop early in life have been shown to predispose 
children to infection. Studies on Schistosoma-infected populations have reported that anti-
Schistosoma IgG4 levels in infected children are associated with higher parasite burdens and 
parasite susceptibility [48, 49].  IgG4 is known to interfere with IgE-induced mast cell and 
eosinophil degranulation through preventing the binding of IgE to the effector cells thereby 
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preventing killing of schistosomula [45], IgG4 will also block IgG1 and IgG3 mediated 
killing of schistosomula by human eosinophils in vitro [36]. Elevated IgG4 levels observed in 
S. haematobium infection compared to uninfected children increase predisposition to 
infection. Following treatment there was a significant decrease (p<0.05) in IgG4 highlighting 
the importance of praziquantel in lowering IgG4 which then results in a significant decline in 
infection at 6 weeks and 2 year post treatment. There is need therefore to carry out further 
studies especially taking into account cytokine levels which are key to facilitating the 
production of both the total and S. haematobium-specific antibodies. 
4.6 Conclusion 
This study confirms findings from previous work by other research groups that treatment 
reduces S. haematobium egg burden and alters immune responses. There was a significant 
reduction in prevalence, intensity to infection and reinfection. Since the study area is a 
moderate zone of transmission without any specific current control program, treatment with 
praziquantel once every 2 years may keep the infection at low level of transmission. Two 
years after praziquantel treatment significant changes occur in total and specific IgG1 as well 
as total and specific IgG4 changes. These findings suggest consequences of praziquantel long 
term effects in changing the overall protective immunity of these school children and benefits 
of the repeated mass drug administration. 
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Tables Legend 
Table4.1: Baseline prevalence and intensity of S. haematobium infection. 
Table 4.2: Prevalence, cure rate and Average Egg Mean Count at baseline, 6 weeks and 2 
years following treatment with praziquantel. 
Table 4.3: Re-infection cases of S. haematobium post-praziquantel treatment. 
Table4. 4: Occurrence of haematuria at baseline and 2 years after praziquantel treatment. 
 
Figures Legend 
Figure 4.1: Concentration of total antibodies at baseline and 2 years post-praziquantel 
treatment. 
Figure4.2: Mean OD values of S. haematobium specific antibodies at baseline and 2 years 
post praziquantel treatment. 
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Table4.1: Baseline S. haematobium infection characteristics, prevalence and intensity of 
infection. 
Parameter S. haematobium 
Infected 
S. haematobium 
Uninfected 
χ2 P value Light 
Infection 
Moderate 
Infection 
Heavy 
Infection 
χ2 P value 
Sex   1.891 0.169    0.297 0.862 
Boys 20(19%) 85(81%)   11(55%) 7(35%) 2(10%)   
Girls 29(27.1%) 78(72.9%)   20(69%) 7(24.1%) 2(6.9%)   
Age Group   0.158 0.691    2.594 0.273 
7-9 19(20%) 76(80%)   13(68.4) 4(21.1%) 2(10.5%)   
10-13 30(25.6%) 87(74.4%)   18(60%) 10(33.3%) 2(6.7%)   
 
 
 
Table 4.2: S.haematobium infection prevalence, cure rate and Average Mean Egg Count at 
baseline, 6 weeks and 2 years following treatment with praziquantel. 
Variable Baseline 6 weeks post treatment 2 years post treatment 
Prevalence 
Cure rate 
49(23.1%) 1(0.47%) 
98% 
1(0.47%) 
97.8% 
Boys 
Cure rate 
20(19%) 1(0.47%) 
95% 
1(0.47%) 
94.7% 
Girls 
Cure rate 
29(27.1%) 0 
100% 
0 
100% 
7-9 
Cure rate 
19(20%) 1(0.47%) 
94.7% 
1(0.47%) 
94.4% 
10-13 
Cure rate 
30(25.6%) 0 
100% 
0 
100% 
Average 
Mean Egg 
Counteggs/ 
10ml urine 
15.9 86.7 2 
 
Table 4.3: Re-infection cases of S. haematobium post-praziquantel treatment. 
 S. haematobium 
infected 
S. 
haematobiumuninfected 
Reinfection Cases 
6 weeks     
Boys 1(0.95%) 104(99.05%) - 
Girls 0(0%) 107(100%) - 
2 years     
Boys 1(0.95%) 103(99.03%) 1(0.96%) 
Girls 0(0%) 107(100%) 0(0%) 
 
Table 4.4: Occurrence of haematuria at baseline and 2 years after praziquantel treatment. 
 Before 
Treatment 
 2 years Post 
treatment 
 
 S. haematobium 
Infected 
S. haematobium 
Uninfected 
S. haematobium 
Infected 
S. haematobium 
Uninfected 
Boys 9(45%) 5(5.9%) 0 0 
Girls 14(48.3%) 4(5.1%) 0 0 
7-9 8(42.1%) 3(3.9%) 0 0 
10-13 15(50%) 6(6.9%) 0 0 
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Figure 4.1: Profiles of total antibodies at baseline and 2 years post-praziquantel 
treatment 
 
 
 
 
Figure4.2: Profiles of S. haematobium specific antibodies at baseline and 2 years post 
praziquantel treatment 
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CHAPTER 5: S. haematobium infection and Chemotherapy-induced changes in IL-6 
and acute phase proteins associated with inflammation in school children in a 
Schistosomiasis- endemic area 
 
After having identified key research gaps with respect to lack of reliable inflammation 
markers associated with schistosomiasis, this Chapter explored acute phase markers that had 
not yet been investigated to the best of our knowledge. Chronic stimulation of inflammation 
is common in children continuously exposed to Schistosoma-infested waters as a result of the 
increase in tissue entrapped eggs that are released. The increase in stimuli that elevates 
inflammation is known to increase production of acute phase proteins.The level of IL-6, the 
chief stimulator of production of acute phase proteins was measured before and after 
treatment with praziquantel to establish the effect of repeated treatment on inflammation. 
We also established if there is a link between the information gathered from the preceding 
chapter on antibody profiles and inflammation markers. We investigated whether individuals 
who are protected against S. haematobium by virtue of elevated protective antibodies are also 
protected against inflammation and also established if those individuals prone to reinfection 
have elevated inflammatory markers which would be expected as they are continuously under 
attack by S. haematobium. 
This chapter is in the format of the target journal. 
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5.1 Abstract 
Background: Acute phase proteins are plasma proteins whose concentration increases or 
decreases as a result of infection or inflammation and their production is stimulated by IL-6. 
Their circulating concentrations in the body reflect the extent of inflammation. There is an 
increased risk of cases of direct and indirect morbidities as a result of stimulation of tissue- 
destructive inflammatory caused by S. haematobium infection, hence the need to determine 
the levels of inflammatory markers in S. haematobium infected children and also determine 
the effect of repeated annual mass treatment on levels of IL-6 and acute phase proteins. 
Methodology: Urine specimens from 212 school children were collected and examined to 
determine prevalence of S.haematobium at baseline and 2 years following annual rounds of 
praziquantel treatment. Levels of 4 acute phase proteins were measured from serum samples 
from the participants using the magnetic bead-based immuno-assays at baseline and 2 years 
following praziquantel treatment. Sandwich ELISA was used to determine levels of IL-6. 
Results: The overall pre-treatment prevalence of S. haematobium infection was 23.1 % at 
baseline and 0.47 % after 2 years of annual treatments. S. haematobium infected children had 
marginally higher levels of procalcitonin and tissue plasminogen activator before treatment 
though the difference of all three was not significant p>0.05 using Mann-Whitney non-
parametric U test. Levels of ferritin and fibrinogen were lower in S haematobium infected 
children before treatment, however the difference was also not significant p>0.05 using 
Mann-Whitney U test.There was no association between infection status or IL-6 and the 
levels acute phase proteins p>0.05 for all acute phase proteins using the Mann-Whitney test. 
Discussion/Conclusion: Findings from this study suggest no bearing of S. haematobium 
infection status on level of acute phase proteins before and after annual treatment with 
praziquantel. The extent of inflammation cannot be determined using ferritin, tissue 
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plasminogen activator and fibrinogen. Levels of IL- 6 did not have any bearing on the levels 
of the acute phase proteins. There is a need to explore other acute phase proteins as 
inflammatory markers in S. haematobium infection. 
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5.2 Introduction 
Schistosomiasis is a water-borne parasitic disease with a global disease burden calculated at 
24–56 million disability-adjusted life-years lost [1]. Chronic inflammation subsequent to 
infection with S. mansoni and S. japonicum, and S. haematobium appears to be the major 
source of burden in individuals with shistosomiasis.  Subtle morbidities such as anaemia, 
growth deficiencies, physical fatigue and diminished cognitive development occur as a result 
of the inflammation [2, 3, 4, 5, 6].There is an increased risk of direct and indirect cases of 
morbidities as a result of stimulation of tissue- destructive inflammatory and granulomatous 
reactions from S. haematobium infection. In children of school going age infected with S. 
haematobium anaemia associated with chronic inflammation is worsened by blood loss seen 
as gross and micro haematuria. In addition to this example of direct morbidity, the 
Schistosoma-infected host can be indirectly predisposed to greater susceptibility to other 
pathogens. For example, there is an increased risk to HIV acquisition in individuals with 
friable sandy patches that are common in female genital schistosomiasis caused by S. 
haematobium infections [5, 7]. 
In the control of parasitic diseases, immune responses and consequently the inflammatory 
processes are meant to eliminate the harmful agent and restrict tissue damage but in some 
situations it may end up triggering pathological repercussions that can also effect injury and 
illness itself. In some instances inflammation can persevere even after the harmful agent has 
been eliminated, giving rise to chronic inflammation [8]. It is evident that immune responses 
and cytokine responses generated during the various stages of the life cycle of the parasite 
account for most of the morbidities culminating in chronic inflammation against schistosome 
antigens that are released from eggs trapped in tissues [9,10]. The location and number of 
eggs lodged in the tissues initially determine the magnitude of inflammation and with time 
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the pathology associated with fibrosis and organ damage [11]. In S. haematobium endemic 
areas, children are exposed to the parasite through water related activities such as swimming 
and those infected continuously have eggs being deposited in their tissues and consequently 
the immunopathological reactions against these eggs trapped leads to an increase in acute 
phase proteins and inflammation. When the agent triggering inflammation occurs repeatedly 
the acute phase response and may be continuously activated and become chronic as the case 
in S. haematobium-endemic areas where there is constant exposure of worms and egg burden. 
Immune reactions to Schistosoma eggs trapped in the tissues in chronically infected cases 
ultimately result in inflammation in affected tissues followed by granuloma formation [11]. 
Praziquantel has become the drug of choice in the treatment of schistosomiasis and it is 
dispensed through mass drug administration programmes around Africa. The drug is effective 
against all schistosome species with minimal detrimental effects to the host and it is also 
effective against other trematode and cestode infections [12]. The mechanism of action is not 
yet fully understood though there is evidence suggesting that it increases the permeability of 
schistosome membranes to calcium thereby promoting tegument damage and worm paralysis 
[13]. The dying parasites are then removed from the host and destroyed by circulating 
immune cells. There is unequivocal evidence that praziquantel treatment minimizes worm 
burden thereby reducing the amount of deposited eggs culminating in an overall decline in 
inflammation related to the immunopathological reactions to the eggs and therefore 
praziquantelshould be able to reduce chronic inflammation especially if administered 
regularly. 
Knowledge of inflammation markers is necessary in assessing and identifying children who 
are likely to develop chronic pathologies later on in life. Chronic inflammation can be seen as 
a continuous series of distinct and consistent inflammatory stimuli. In such conditions, 
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increased serum concentrations of acute phase proteins and proinflammatory cytokines are 
generally observed [14]. 
Acute phase proteins are a group of plasma proteins derived primarily from the liver and they 
are involved in the inhibition of infection, mediating systemic effects like fever, leucocytosis, 
increased cortisol, decreased serum iron, and many others [15].The extent of inflammatory 
tissue damage as well as diagnostic and prognostic information in some human diseases can 
be resolved by measurement of acute phase proteins [16,17]. Bacterial infections [18], 
neoplasia, [19] and inflammatory bowel diseases (IBD) have employed measurements of 
acute phase proteinsin their prognosis [20]. However there is inadequate information 
regarding the use of acute phase proteins in parasitic infections like in human Schistosoma 
infection [21, 22]. This is unusual considering the fact that parasitic infections elicit 
considerable inflammation.  
Circulating microbial products are well known inducers of acute phase proteins [23], thus, in 
S. haematobium infected children the microbial products from the natural death of the 
schisitosomes and those released following praziquantel treatment might induce 
overproduction of acute phase proteins. In this study, fibrinogen, ferritin and tissue 
plasminogen activator are going to be evaluated before and after treatment with praziquantel. 
Acute phase proteins have varying half-lives, rising and falling at different times, which limit 
the use of only one biomarker in determining inflammation. Thus the simultaneous 
measurements could be most effective in identifying individuals prone to chronic 
inflammation. 
Traditional biomarkers such as C-reactive protein, serum amyloid A and haptoglobulin have 
produced conflicting results in terms of correlation between inflammation and 
schistosomiasis and insufficiently sensitive or specific enough to guide treatment decisions in 
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infectious diseases.Some studies have reported a direct relationship between schistosomiasis 
and presence of the acute phase proteins [24, 25, 26] whilst other researchers have found no 
link between the two.  To our knowledge the combination of tissue plasminogen activator, 
fibrinogen, ferritin and procalcitonin has not been evaluated in individuals living in 
schistosomiasis endemic areas. Recently, there has been interest in the potential use of 
procalcitonin and ferritin as inflammatory markers in various infectious diseases as a result of 
the increase of both retrospective and prospective studies that consistently have documented 
elevated serum concentrations of procalcitonin and ferritin in various parasitic infection. 
Acute phase proteins are released as a result of the action of cytokines such as IL-1, IL-6, and 
TNF-α produced byT-lymphocytes, macrophages, monocytes, endothelial cells, and 
fibroblasts at the site of inflammatory lesions. Although it is evident that a number of 
proinflammatory and anti-inflammatory cytokines are involved in the inflammatory response 
[27], available data indicates that IL-6 is the supreme stimulator [21, 28]. Acute inflammation 
turns into chronic inflammation if the activity of IL-6 perseveres. However, in knockout mice 
incapable of expressing IL-6, the role of IL-6 in triggering the production of acute-phase 
proteins depends on the nature or site of the inflammatory stimulus; the response is largely 
inhibited in IL-6 knockout mice injected with turpentine but is normal when bacterial 
lipopolysaccharide is the inflammatory stimulus [22]. Unrestrained and sustained action of 
cytokines is potentially harmful. Anti-cytokine therapies are thus useful in light of the role of 
proinflammatory cytokines in inflammation-related pathologies and this may have far 
reaching consequences in schistosomiasis vaccine development which has been elusive [29]. 
Identifying individuals at an early stage who are vulnerable to inflammation allows better 
prognosis and prevents the use of invasive, costly and time consuming procedures to 
determine those suffering from pathological complications of chronic inflammation 
conditions. It has been demonstrated that biomarkers; C-reactive protein and faecal 
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calprotectin can be used to evaluate disease status in patients with inflammatory bowel 
disease (IBD) though endoscopic evaluation which is expensive and invasive is the gold 
standard [30]. The goal of disease monitoring is to identify individuals at risk in order to treat 
earlier.  
Although perpetual and continuous inflammation is presumed to be a hallmark of 
schistosomiasis, very few studies have actually examined the acute phase proteins 
simultaneously with the proinflammatory cytokine IL-6 in S. haematobium infections. In this 
study S.haematobium infections were first determined then ferritin, fibrinogen, tissue 
plasminogen activator, procalcitonin and IL-6 were determined at baseline to assess 
inflammation in both S. haematobium-infected and S.haematobium uninfected school 
children. Secondly we established if repeated rounds of praziquantel treatment for 2years 
results in changes in the acute phase proteins and IL-6. 
5.3 Methodology 
Study population and design 
The study was carried out at Bandanyenje primary school, a rural school situated in 
Manicaland Province in Zimbabwe. The study population comprised of 212 (105 boys and 
107 girls) aged between 7–13 years, who were permanent residents of the area. The study 
design is a “before and after treatment”. Serum samples from the participants were taken and 
measurement of acute phase proteinsand IL-6 before and after praziquantel treatment. 
Parasitology and blood sampling 
A school-based longitudinal intervention study was conducted and involved examination and 
treatment of the study population at baseline, 6 weeks and at 2 year follow up surveys. Stool 
and urine samples were collected from 212 school children at baseline and follow up on three 
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consecutive days and were processed for schistosomiasis using the Kato Katz by Peters et al. 
(1980) [31] and the filtration technique Mott et al. (1982) [32] respectively. Blood samples 
were collected from the 212 children at baseline and 2 years post-treatment and their serum 
was used to determine acute phase proteins and IL-6.  
Praziquantel Treatment 
All 212 school children were given praziquantel (40mg/kg body weight) at baseline 
regardless of the infection status. Praziquantel was administered at the same dose in all the 
children annually for 2 years. 
IL-6 determination 
The analysis of IL-6 in the serum samples was done by sandwich ELISA. 100 ul of coating 
antibody was added into the wells of a 96 well ELISA plate. The plate was then covered with 
adhesive to prevent evaporation and incubated overnight at 4oC. After incubation the plate 
was turned over to remove the coating antibody and was washed thrice with the wash buffer. 
The plate was dried by blotting on a paper towel to remove residual wash solution.200ul of 
5% egg albumin was added to all the wells to block nonspecific binding sites. The plate was 
covered with adhesive tape and incubated for 1 hour at room temperature on a plate shaker. 
After incubation the plate was turned over to remove the coating antibody and was washed 
thrice with the wash buffer. The plate was dried by blotting on a paper towel to remove 
residual wash solution. 100 ul of the sample was added into wells in duplicate. The plate was 
covered with adhesive tape and incubated for 2 hours at room temperature on a plate shaker. 
After incubation the plate was turned over to remove the sample and was washed thrice with 
the wash buffer. The plate was dried by blotting on a paper towel to remove residual wash 
solution.100 ul of biotin conjugated antibody was added into the wells. The plate was covered 
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with adhesive tape and incubated for 1 hour at room temperature on a plate shaker. After 
incubation the plate was turned over to remove the detection antibody and was washed thrice 
with the wash buffer. The plate was dried by blotting on a paper towel to remove residual 
wash solution.100 ul of Horse Radish peroxidase (HRP) antibody was added into the wells. 
The plate was covered with adhesive tape and incubated for 1 hour at room temperature on a 
plate shaker. After incubation the plate was turned over to remove the HRP conjugate 
antibody and was washed six times with the wash buffer. The washing was done thoroughly 
to remove all unbound HRP conjugate antibodies. The plate was dried by blotting on a paper 
towel to remove residual wash solution.100 ul of o- Phenlylenediamine Dihydrochloride 
(OPD) substrate was added to the plate and incubated for 20 minutes in the dark. The plate 
was covered with a foil paper to prevent light from interrupting with the reaction. After 
incubation 20ul of the stop solution was then added to each well. The plates OD was read at 
dual wavelength for cytokine analysis (405nm and 630nm) in an ELISA plate reader. 
 
Acute Phase Proteins determination 
Serum levels of ferritin, fibrinogen, tissue plasminogen activator and procalcitonin, were 
determined by  the magnetic bead–based immuno-assays using the Bio-Plex Pro™ human 
acute phase 4-plex immunoassay complete commercial kits.25ul 1x beads were added to a 96 
well micro titer plate and vacuum filtration was carried out. The standards, samples and 
controls were diluted and 50 ul added to the wells and incubated in the dark at room 
temperature with shaking at 850 rpm for 1 hour. After incubating the beads, samples, 
standards, blank, and controls vacuum filtration was done and the plate was washed three 
times with 100ul wash buffer. 25ul of 1x detection antibodies were added to the assay plate 
and incubated in the dark for 30min with shaking at 850rpm. The plate was washed 3x and 
Streptavidin –PE was added. The assay plate was incubated for 10 min at room temperature 
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with shaking at 850 rpm. Vaccum filtration was done and the plate was washed 3x and the 
beads were re-suspended in assay buffer prior to reading the plate. The Bio-plex manager 
software was used for running the assay, data acquisition and analysis. 
Statistical analysis 
Data was analysed using SPSS statistical software v16. Levels of serum levels of ferritin, 
fibrinogen, tissue plasminogen activator, procalcitonin and IL-6 at baseline and 2 years post-
treatment in the school children were compared using student t test to determine the effect of 
praziquantel treatment on acute phase proteins and IL-6.  
The Mann–Whitney non parametric U-test was used to determine the effect of S. 
haematobium infection on the levels of ferritin, fibrinogen, tissue plasminogen activator, 
procalcitonin and IL-6. A value of p < 0.05 was considered to indicate a significant difference 
in statistical analyses. 
5.4 Results 
212(105 boys and 107 girls) aged between 7-13 were recruited in the study and were 
successfully traced and re-examined at both follow-ups with complete sets of longitudinal 
parasitological data on S. haematobium infection.The overall pre-treatment prevalence of S. 
haematobium infection was 49(23.1 %) with 20(19%) boys and 29(27.1%) girls as 
determined using the urine filtration technique (Table 5.1).There was an overall decline in S. 
haematobium prevalence from 23.1% at baseline to 0.47% % at 6 weeks post-treatment and, 
0.47% 2 years post-treatment, an overall 87.1% reduction over 2 years (p< 0.05). A total of 
211(99.5%) children were egg negative after treatment. 
No significant changes were observed in ferritin, tissue plasminogen activator and 
procalcitonin among the S. haematobium positive and negative children (p>0.05, Mann-
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Whitney non parametric test at baseline (Figure 5.1). Following repeated rounds of annual 
treatment changes occurred in the levels of the acute phase proteins though they were all 
insignificant with respect to infection status p>0.05- Mann-Whitney non parametric test 
(Figure 5.3). Tissue plasminogen activator and procalcitonin levels increased slightly 
following treatment. In S. haematobium-uninfected children, levels of procalcitonin 
decreased following treatment though it was insignificant (p>0.05) whilst the ferritin and 
tissue plasminogen activator marginally increased following treatment. 
The Mann-Whitney test was used to determine the effect of S.haematobium infection on the 
levels of acute phase proteins. S. haematobium-infected children had slightly higher levels of 
procalcitonin and tissue plasminogen activator before treatment though the difference of all 
three was not significant p>0.05- Mann- Whitney non parametric test (Figure 5.1). Levels of 
ferritin and fibrinogen were lower in S haematobium positive children before treatment, 
however the difference was also not significant p>0.05 (Figure 5.1 and Figure 5.2). 
Infection status had no bearing on the levels acute phase proteins, using the Mann-Whitney 
non parametric test, ferritin levels (p=0.364), tissue plasminogen activator (p=0.192), 
procalcitonin (p=0.232) were shown to be unrelated to S. haematobium infection. Fibrinogen 
levels were within normal ranges for both S. haematobium positive and negative children and 
there the Mann-Whitney test could not be performed because there was only one group 
(Figure 5.2). 
In order to determine the effect of treatment on the acute phase proteins the student t test was 
performed. In S haematobium positive children there was a decrease in ferritin levels 
following treatment though it was insignificant p=0.357, however in S. haematobium 
negative children there was a slight increase which was also not significant (p>0.05). There 
was an insignificant increase in procalcitonin and tissue plasminogen (p=0.226 and p=0.186 
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respectively) following praziquantel treatment in both S. haematobium and positive and 
negative children (Figure 5.3). 
At baseline level of IL-6 was higher in S. haematobium infected children than in S 
haematobium uninfected children though the difference was insignificant (p<0.05) (Figure 
5.4). Following treatment there was an increase in IL-6 in S. haematobium uninfected 
children and a decrease in IL-6 in S. haematobium uninfected children, however the changes 
were insignificant p<0.05  in both cases. The Mann Whitney test was used to determine the 
effect of IL-6 on the levels of the acute phase proteins. IL-6 levels did not have an effect on 
the levels of ferritin, procalcitonin and tissue plasminogen activator (p= 0.334, p=0134 and 
p=0.847, respectively usingMann-Whitney test). Effect of IL-6 on fibrinogen levels could not 
be determined by the Mann-Whitney test because fibrinogen levels were within normal 
ranges for all the children. 
5.5 Discussion 
The S. haematobium prevalence was 23.1% which is slightly lower than 23.8% recorded in 
the province by Midzi et al, 2014 [33]. The prevalence of S. haematobium infection declined 
from 23.1% to 0.47% following repeated rounds of annual praziquantel treatments (Table 
5.1). This decline in prevalence resulted in a decline in the S. haematobium worms laying the 
eggs because of worm damage caused by praziquantel. The eggs are responsible for invoking 
and determining the magnitude of inflammation within tissues [34]. The low levels of acute 
phase proteins post treatment reflect the low prevalence of infection 2 years following 
repeated rounds of annual praziquantel treatment. If less children are infected (less exposure 
of S. haematobium eggs in tissues), the extent of inflammation will be reduced since the 
tissue-trapped eggs are responsible for inflammation.  
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The current study was the first in reporting the relationship between fibrinogen, ferritin, 
procalcitonin and tissue plasminogen activator and S. haematobium infection in school-going 
children. The effect of IL-6 on the circulating four acute phase proteins was also reported for 
the first time in this study. This study was motivated in part by the limited information 
regarding relationships between biomarkers of inflammation and S. haematobium infection. 
Contrary to what was expected, we observed no association between S. haematobium 
infection status and the inflammatory markers (Figure 5.1 and Figure 5.2); fibrinogen, 
ferritin, tissue plasminogen activator and procalcitonin before treatment with praziquantel. 
Using the Mann-Whitney non parametric test all four acute phase proteins did not show any 
association with S. haematobium infection status. Repeated exposure to inflammatory agents, 
common in schistosomiasis endemic settings where there is frequent exposure to cercariae 
infested water is expected to result in constant elevations in acute-phase proteins and other 
inflammatory markers. Previous studies had reported relationships between S. haematobium 
and other acute phase proteins albeit with conflicting results. It is against this background that 
we evaluated the levels of the four acute phase proteins. Positive associations between levels 
of acute phase proteins such as C-reactive protein and hepcidin and Schistosoma infections 
have been reported [24, 25]. Ferritin has also been reported to be raised in inflammatory 
diseases [26] but such an association was not evident in our study though in the reported case 
the prevalence of S. haematobium was high. Our observation can be attributed to the 
moderate prevalence in our study group or simply just that other markers like C-reactive 
protein are better markers than the markers we evaluated.The expectation that a combination 
of more than one measure would perform substantially better than any single one was not 
supported by our observations. Following repeated treatment with praziquantel, no significant 
changes were observed in the acute phase proteins regardless of infection status (Figure 5.3). 
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Serum concentration of acute phase proteins typically peak within 24 to 48 h after the 
initiation with a decline coinciding with the recovery from the infection. It has been noted 
that acute phase proteins decline within 4–7 days after the initial stimulus if no further 
stimulus occurs and that repeated exposure to the agent stimulating inflammation results in 
chronic inflammation with levels of acute phase proteins being continuously elevated [35]. 
Circulating acute phase levels are felt to be a reflection of the response to pro-inflammatory 
cytokines such as IL-6 [15, 28]. There were no significant differences in circulating IL-6 
between S. haematobium infected  and uninfected  school children and the levels in both 
groups were not high (Figure5.4). Inflammation with T-cell activation is a distinct 
characteristic of S. haematobium infection and as such, markers of inflammation are expected 
to be in circulation [36, 37]. A Th2 immune response is induced by schistosomes through 
Th1 down-regulation via increased IL-6 production. Host macrophages recognize the larvae 
of schistosomes which induces secretion of IL-6. In children who are S. haematobium 
positive induction of the Th2 response would be expected resulting in increased production of 
IL 6 [38]. 
Following treatment there were no significant changes in the level of IL-6 (Figure 5.4). This 
was unexpected especially considering the fact that studies have shown that treatment of 
schistosomiasis with praziquantel induces noticeable changes in cytokine levels [39, 40]. 
Marked changes in cytokines such as IL-6, IL-4, IL-5 and IL-10 occur following treatment of 
schistosomiasis induces marked changes in cytokine levels resulting in a shift to Th2 
responses which have been associated with resistance to reinfection [41]. Exploring other 
cytokines not included in this study (i.e., IL-4, IL-5, and IL-13) is important in understanding 
the immune response to multiple parasitic infections and should be integrated in future 
research efforts. 
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Our study revealed novel insights in the use of the four acute phase proteins in evaluating 
inflammation in S. haematobium, albeit with some minor limitations such as sample size and 
availability of resources. General limitations of assessing serum levels of inflammatory 
markers such as acute phase proteins and cytokines are the relatively non-specificity, short 
half-life, nonspecific induction, and serum levels not reflecting biologic activity [42]. 
Notwithstanding these limitations, serum levels of some of these biomarkers have yielded 
important insights in the level of inflammation in parasitic diseases. 
5.6Conclusion 
The central question in this study was whether IL-6, ferritin, fibrinogen, tissue plasminogen 
activator and procalcitonin are suitable as identifiers for inflammation in S. haematobium 
infection and whether their levels would change following repeated rounds of annual 
praziquantel treatments. Our results showed no significant association between S. 
haematobium infection status and level of the four acute phase proteins ferritin, fibrinogen, 
tissue plasminogen activator and procalcitonin.  However, marginal increases were observed 
in levels of procalcitonin and tissue plasminogen activator in S. haematobium infected 
children. Treatment using praziquantel did not significantly affect the levels of the four acute 
phase proteins.There is a need to identify and select of the most appropriate biomarkers of 
inflammation in children since identifying individuals who are vulnerable early stages of 
inflammation allows better prognosis and prevents the use of invasive, costly and time 
consuming procedures to determine those suffering from pathological complications of 
chronic inflammation conditions in future. 
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Tables Legend 
Table5.1: Overall prevalence of S. haematobium infection in the study population 
according to gender at baseline and 2 years post praziquantel treatment. 
 
Figures Legend 
Figure 5.1: Mean concentration of acute phase proteins in S. haematobium-infected 
and uninfected children at baseline. 
Figure5.2: Mean concentration of fibrinogen in S. haematobium infected and 
uninfected children at baseline. 
Figure5.3: Mean concentration of acute phase proteins in S. haematobium infected 
and uninfected children at baseline and 2 years post praziquantel treatment. 
Figure 5.4: Mean IL-6 OD values in S. haematobium infected and uninfected children 
at baseline and 2 years post praziquantel treatment. 
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Table 5.1: Overall prevalence of S. haematobium infection in the study population 
according to gender at baseline and 2 years post praziquantel treatment. 
Variable Baseline 6 weeks post treatment 2 years post treatment 
Prevalence 
Cure rate 
49(23.1%) 1(0.47%) 
98% 
1(0.47%) 
97.8% 
Boys 
Cure rate 
20(19%) 1(0.47%) 
95% 
1(0.47%) 
94.7% 
Girls 
Cure rate 
29(27.1%) 0 
100% 
0 
100% 
 
 
Figure 5.1: Mean concentration of acute phase proteins in S. haematobium-infected and 
uninfected children at baseline 
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Figure 5.2:Mean concentration of fibrinogen in S. haematobium infected and uninfected 
children at baseline 
 
 
Figure 5.3: Mean concentration of acute phase proteins in S. haematobium infected and 
uninfected children at baseline and 2 years post praziquantel treatment. 
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Figure 5.4: Mean OD values for IL 6 in S. haematobium infected and uninfected 
children before and after treatment with praziquantel. 
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CHAPTER 6: OVERALL DISCUSSION, CONCLUSIONS AND 
RECOMMENDATIONS 
6.1 General overview 
This study investigated the schistosomiasis markers of inflammation through the use of four 
acute phase proteins and antibody profiles in school children on repeated annual mass 
treatment using the anti-helminthic drug praziquantel in Bandanyenje. Schistosomiasis is a 
devastating parasitic disease which if untreated results in severe morbidities such as 
obstructive uropathy, renal failure, hydroureter, hydronephrosis, and bladder cancer later on 
in life [1, 2]. Prevalence of S. haematobium our area of study, at was 23.1% was marginally 
lower than that of the overall prevalence in Manicaland province (23.8%) [3].The prevalence 
of S. haematobium reported in this study could reflect on-going control efforts in the area 
with the Ministry of Health taking part in schistosomiasis awareness campaigns. Zimbabwe 
was experiencing dry spells during the study period with erratic rainfall patterns because of 
the drought. This could have attributed to the moderate prevalence because of the reduced 
transmission of S. haematobium when water levels are low. There is a need to maintain a low 
prevalence as this prevents Schistosoma-related morbidities as the children grow up. Children 
are mainly affected because of their higher rates of water related activities, immunological 
status and anatomical vasculature [4, 5] and infected children suffer from haematuria, 
dysuria, nutritional deficiencies, anaemia, growth retardation, decreased physical 
performance and impaired memory and cognition as a result of extreme schistosome 
infections [6]. Presence of haematuria, measure of schistosome-induced pathology, before 
treatment was correlated (χ2=20.38, p<0.05) with the presence of S.haematobium egg count 
in urine. In our study haematuria, was reduced from 30% (S. haematobium-infected) and 
12.1% (S. haematobium-uninfected) to 0%, 2 years after treatment highlighting the 
effectiveness of praziquantel.  
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In our study, the pronounced cure rates after 2 years of annual treatment could be attributed 
to the study period, baseline infection intensity, geographical location, repeated rounds with 
enhanced killing of schistosomula and the method of laboratory diagnosis employed, ie 
microscopy with egg determination does not rule out presence of the worm. After annual 
praziquantel treatment for 2 years the prevalence was 0.47%. This reflects the efficacy of 
praziquantel as well as the benefits of repeated annual treatment. Infective cercariae are 
destroyed at a faster rate in children who regularly take inpraziquantel. Schools have been 
targeted for mass treatments because of the increased benefits of reducing infection burdens 
in children compared to adults and the simplicity of providing treatment.  
 Our group also wanted to determine whether there are any antibody profiles that protect or 
predispose children to S. haematobium hence general and S. haematobium specific antibodies 
were measured in both S. haematobium positive and negative children. Adult schistosome 
worms live for many years in the human blood stream, but treatment disrupts the integrity of 
the worm's outer tegument exposing a range of formerly cryptic antigens to the host's 
immune system. The post-treatment IgE levels induced by cryptic antigens can be more 
strongly associated with re-infection immunity and multiple rounds of treatment have been 
found to increase resistance [7, 8]. At baseline there was an increase in total IgG4 whilst all 
the other immunoglobulins were within normal ranges. Other studies have revealed 
hypergammaglobunaemia with noteworthy increases in IgG4 and IgE though in 
Schistosomiasis infected individuals [9, 10].   In our study group, upon treatment there was an 
expected significant decline in IgG4 though there was an unexpected absence of changes in 
Schistosoma-specific IgE. IgG4 is known to block the crosslinking of IgE and prevent the 
antibody dependant cytotoxicity of parasites however; the increase in total immunoglobulins 
is non-specific and can be affected by other invading pathogens, which is common in 
children living in poverty-stricken areas. We also observed an increase in both the total and 
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specific IgG1 which was maintained over the 2 years, which suggests that IgG1 could have 
been stimulated by antigens produced from the worms after chemotherapy. Khalife et al., 
1989 [11] demonstrated the eosinophil-dependent killing of schistosomula releases sub-
surface antigens which stimulates IgG1 production. This could explain the significant 
increase of IgG1 following treatment with praziquantel. IgG1 is stimulated by praziquantel 
induced release of sub-surface antigens as well as a decline in eggs produced.  An increase in 
IgG1 following treatment with praziquantel was observed by Mutapi et al., 1998 [12] which 
they attributed to a switch from IgA specific antibodies to IgG1 response that occurs in 
children. The switch is accelerated by the praziquantel treatment which actually causes partial 
protection to reinfection as seen by the low 0.96 % reinfection rate 2 years post treatment in 
this study. Praziquantel has been shown to boost responses in IgG1, IgE and cytokines IL-4 
and IL-5 which have been associated with protection against reinfection [13]. Re-infection in 
our study was very low (0.96%) and this can be attributed to the repeated treatment with 
praziquantel, lifestyle changes in children due to increased awareness of dangers of 
schistosomiasis and also to the moderate prevalence (23.1%) in the region.  
Most studies have reported IgE association with resistance to reinfection with significant 
increases in Schistosoma-specific IgE in individuals who are resistant to reinfection with S. 
haematobium, however this was not evident in our study. Production of large amounts of 
specific IgE is a characteristic feature of schistosomiasis [14] and IgE mediated killing has 
been observed in animal experiments [15]. Several studies have shown that low levels of 
reinfection are correlated to higher serum levels of Schistosoma-specific IgE [16, 17].  
We were interested in evaluating the four acute phase proteins and their association with IL- 
6, a pro inflammatory marker. However from our results we could not establish a direct 
relationship between the pro inflammatory cytokine IL-6 and acute phase biomarkers. This 
could have been linked to the short half live of acute phase proteins coupled with the fact that 
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the prevalence and intensity of infection and reinfection was low. Following annual 
praziquantel treatment, there were no significant changes in acute phase proteins and IL-6. 
This is in contrast to what other studies have reported. Marked changes in cytokines such as 
IL-6 have been shown to occur following treatment of schistosomiasis with a shift to Th2 
responses which have been associated with resistance to reinfection [18]. Some studies have 
reported elevated levels of acute phase proteins such as C-reactive protein and hepcidin in 
schistosomiasis infected individuals with a decrease in the levels of the acute phase proteins 
occurring following treatment with praziquantel [19, 20]. Our observation, which is in 
contrast to such observations, can be attributed to the moderate prevalence in our study group 
or simply that other markers like C-reactive protein are better markers than the markers we 
evaluated. 
There were some interesting cases from the study group with notable results. Only 1 child 
was still infected after 2 years and interestingly this child had a heavy infection at 6 weeks 
after the initial treatment. Not only was the individual still infected after repeated treatments, 
he had an antibody response significant of susceptibility to infection and reinfection and had 
a post treatment increase in all the four acute phase proteins.  He had the highest levels of the 
blocking Schistosoma-specific IgG4 antibodies that were still very high after repeated rounds 
of treatment. He also had very low protective Schistosoma-specific IgE antibodies. IgE levels 
are known to be associated with protection against infection by schistosomes resulting in 
resistance to infection and reinfection. Interestingly at baseline he had undetectable levels of 
all for acute phase proteins, however after 2 years all the acute had risen with high levels 
recorded for fibrinogen, tissue plasminogen activator and procalcitonin. Such results can 
indicate unique host factors that make the individual susceptible to infection or social 
activities the child engages in which predispose him to infection. The level of IL-6 in this 
individual was also high at baseline and following treatment, however the IL-6 values of the 
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other S. haematobium positive and negative children showed insignificant associations with 
acute phase proteins. 
6.2 Strengths and Limitations 
We managed to follow up 212 children over 2 years and the school children were providing 
the required samples needed for us to conduct our studies. Other studies have recorded high 
attrition rates as children drop out of such longitudinal studies making it difficult for 
researchers to draw conclusion from such studies. This could be attributed to the sample 
population which involves school children who rarely migrate to different locations once they 
start school. 
In antibody profiling and acute phase proteins determination we used the multi-plex magnetic 
bead assay which is highly sensitive and can measure the concentrations of several anayltes 
in a small sample with great precision. The only challenge was that the specimens had to be 
stored after sampling and then transported from Zimbabwe to University of KwaZulu Natal, 
South Africa for analysis.  
A case-control approach to this study would have strengthened the study objective of 
realising the importance of repeated mass treatments using praziquantel on antibody profiles 
and inflammation markers. Comparison of untreated schistosomiasiasis-exposed children 
with those on mass treatments could have reinforced the impact of mass treatment campaigns. 
However, our study was part of the National Schistosomiais Control programme which 
required the treatment of all children regardless of exposure status. 
6.3 Conclusion 
In conclusion, our study showed that repeated annual treatments reduce S. haematobium 
infection significantly with corresponding significant changes in total and specific S. 
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haematobium antibodies. These findings suggest consequences of long term effects of 
praziquantel in changing the overall protective immunity of these school children and 
benefits of the repeated mass drug administration. Significant levels of the blocking and 
protective antibodies were detected post treatment which also indicated immunizing effect of 
the praziquantel treatment. While no clear trends could be deduced from the profiles of other 
total and specific antibodies. Our results show no significant association between S. 
haematobium infection status and level of the four acute phase proteins ferritin, fibrinogen, 
tissue plasminogen activator and procalcitonin.  Treatment using praziquantel did not 
significantly affect the levels of the four acute phase proteins 
6.4 Recommendations 
The WHO guidelines recommend treatment with praziquantel once every 2 years in school 
children in communities with a schistosomiasis prevalence of 10% to 50% as such school 
children in Bandanyenje should be given praziquantel biennially [21]. Our findings suggest 
that administration of praziquantel should be biennially according to the WHO 
recommendation. 
Exploring other cytokines not included in this study (i.e., IL-4, IL-5, and IL-13) and 
important in understanding the immune response to multiple parasitic infections should be 
integrated in future research efforts. Anti-cytokine therapies are useful in light of the role of 
proinflammatory cytokines in inflammation-related pathologies and this may have far 
reaching consequences inschistosomiasis vaccine development which has been elusive [22]. 
Our results clearly stress the limitations of acute phase biomarkers for the purpose of 
identifying individuals experiencing inflammatory states who are likely to be affected by 
Schistosoma- associated morbidities later on in life. We also suggest that further research 
efforts should be pursued to identify other appropriate biomarkers that would perform more 
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efficiently in endemic populations. Identifying individuals who are vulnerable in the early 
stages of inflammation allows for better prognosis and prevents the use of invasive, costly 
and time consuming procedures to determine those suffering from pathological complications 
of chronic inflammation conditions in future. 
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Chapter 7: APPENDICES 
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7.3: Specimen storage informed consent form 
 
Universtity of Zimbabwe  
  
 
SPECIMEN STORAGE INFORMED CONSENT FORM 
 
STUDY TITLE: 
Investigating Schistosomiasis Markers Of Inflammation And Immune Responses In 
Individuals On Repeated Mass Drug Administration 
 
Protocol Version: Ver1. 01.11.2012 
 
SPECIMEN STORAGE 
Consent Version  
(English) 
 
PRINCIPAL INVESTIGATOR: Mr T. Chisango 
PHONE: 0772731322 
INTRODUCTION: 
You have decided to take part in the investigational research study named above, sponsored 
by the University of Zimbabwe and Ministry of Health & Chid Welfare.  While your child is 
in this study, blood 2.5 – 5 mls will be collected from your child. You are kindly being 
asked to agree to the storage of these samples for use during the study and after the 
study has ended. We may also ship these samples to another laboratory outside 
Zimbabwe if the need comes. This consent form gives you information about the 
collection, storage, and use of these samples.  These samples will be useful in the first 
next 5 years the Mass Drug Administration of praziquantel research programme is running. 
UUNIVERSITY OF ZIMBABWE 
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The study staff will talk to you about this information.  Please ask if you have any 
questions.  You will be asked to sign or make your mark on this form to indicate whether 
you agree to have your child’s samples stored and tested.  You will be offered a copy of this 
form to keep. 
YOUR PARTICIPATION IS VOLUNTARY: 
Allowing your samples to be stored is completely voluntary.  You may decide not 
to have any samples stored other than what is needed to complete this study and still be in this 
research study or any future study. 
Even if you decide now that your samples can be stored for the duration of the research, you 
may change your mind at any time.  If this happens, you must tell the study staff that you have 
changed your mind.  If you decide not to have your samples stored or used for future 
research, they will be destroyed at the end of the study.   
PURPOSE: 
The specific research to be done on your blood samples will be to analyse for markers of 
allergic reactions after treatment.   The samples will only be used to look for antibodies as 
markers of reaction and effect of treatment on the infections, damage caused by infection, or 
how your body reacts to the infection.  For example, the tests may look at cells, proteins, and 
other chemicals in your body.  Tests may also examine your genes (DNA), since they might 
affect your response to parasitic infection in important ways.  For example, your genes may 
make you more or less susceptible to becoming infected, your responses to infection or to 
treatment stronger or weaker, or make development of allergic reactions progress faster or 
slower.  No other kinds of genetic test will be done by anyone on your stored specimens 
without first explaining the test to you and obtaining your permission. 
The study researchers do not plan to contact you or your regular doctor with any results from 
tests done on your stored samples.  This is because research tests are often done using 
experimental procedures, so the results may not help for making decisions on managing your 
health.  In the very rare case that a specific test result gives important information about your 
health, the researchers will contact you.  If you wish to be contacted with this type of test 
result, you must give the study staff any change to your contact information.  If you have a 
regular doctor and you want the study staff to tell this doctor your child’s test results, you 
must give the study staff your doctor’s contact information. 
Your samples will not be sold or used directly to produce commercial products. 
Research studies using your samples will be reviewed by the Medical Research Council of 
Zimbabwe. 
PROCEDURES: 
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Each time your child’s blood is drawn, up to 5 mL (which is about 1.5 teaspoons) of the 
sample may be stored.  For each sample of blood, part of the sample will be tested 
immediately and the rest will be stored. 
Your blood will be stored safely and securely in a storage facility at the University of 
Zimbabwe-Biochemistry Department.  Only the people who work at the facility and 
approved researchers will have access to your samples.  The people who work at the 
facility will not have any information that identifies you.  The approved researchers 
may be given information about you such as your age and sex, but they will not be 
given your name or any other information that identifies you. Your samples may be shipped 
to approved researchers who work outside of Zimbabwe, if the need arises for some 
specialized assays not available in Zimbabwe. There is no time limit on how long your samples 
will be stored but we anticipate during duration of the MDA. 
RISKS and/or DISCOMFORTS: 
There are few risks related to storing your samples.  When tests are done on the stored 
samples there is a rare but possible risk to your privacy.  It is possible that if others 
found out information about you that is learned from tests (such as information about your 
genes) it could cause you problems with your family (having a family member learn about a 
disease that may be passed on in families). 
POTENTIAL BENEFITS: 
There are no direct benefits to you from having your child’s samples stored.  You and others 
could benefit in the future from research done on these samples. 
CONFIDENTIALITY: 
To keep your information private, your samples will be labelled with a code that can only be 
traced back to your study clinic.  Your name, where you live, and other personal 
information will be protected by the study clinic.  When researchers are given your stored 
samples, they will not be given your personal information. Every effort will be made 
to keep your personal information confidential. 
Efforts will be made to keep your study records and test results confidential. You will be 
identified by a code, and personal information from your records will not be released without 
your written permission.  Any publication of this study will not use your name or 
identify you personally. 
PROBLEMS OR QUESTIONS: 
For questions about the storage of your samples, contact: 
 The PI: Tawanda J Chisango 
Biochemistry Department,  
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University of Zimbabwe 
Churchill/University Ave 
P.O. Box MP 167 
Mount Pleasant, Harare 
Ph: 0773633682 
For questions about your rights as a research subject, contact: 
 Medical Research Council of Zimbabwe 
National Institute of Health Research  
Cnr Mazoe Street/ Josiah Tongogara Avenue 
Harare 
Ph :+263 4 791792, 791193 
Cell : +263  912 433 166 
 
SIGNATURE PAGE 
CONSENT FOR SPECIMEN STORAGE  
Please carefully read the statements below (or have them read to you) and think about your 
choice.  No matter what you decide it will not affect whether you can be in the research study, 
or your routine health care. 
________ I agree to have samples of my child’s blood sample, stored and used for future 
testing related to allergy & autoimmunity. 
________ I agree to have samples of my child’s blood sample, stored and used for future 
testing related to allergy and autoimmunity.  However, I do not agree to have 
genetic testing performed on my samples. 
________ I do not agree to have samples of my child’s blood, stored and used for future 
testing related to allergy and autoimmunity. 
 
   
Name of Child (please print)   
 
 
 
105 
 
   ____________________________________ 
Parent’s/Guardian’s Name (print)  Signature or Mark and Date 
 
 
 
   ____________________________________ 
Study Staff Conducting    Study Staff Signature and Date 
Consent Discussion (print) 
 
 
 
   ____________________________________ 
Witness Name (print)    Witness Signature and Date 
(As appropriate) 
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7.4: Informed consent form for for parental consent (Shona version) 
   
  
 
MRCZ/A/1958  
 
BVUMIDZO YEVABEREKI 
 
 
MUSORO WECHIRONGWA 
KUONGORORWA KWEUVHUTIRO MUVANA VARIKURAPWA CHIRWERE 
CHECHIPFUNGA 
 
 
 
Mutungamiri wechirongwa: Mr T Chisango (MSc)-0772731322 
Vatevedzi : Professor Takafira Mduluza, [PhD]- 0773633682 
   Dr B Ndlovu. [PhD]- 27-31-788424574 
 
 
Zvamunofanira kuziva nezvechirongwa ichi: 
 
 Tinokupai   chibvumirano  ichi  kuti muverenge  pamusoro pechinangwa,  
zvingangonetsa,  uye  nezvingangobatsira  muongororo iyi. 
 Zvirongwa  zvinoitwa zvinozobva  pane  ruzivo rutsva rwakanakisa rwatinenge  
tavanarwo 
 Chinangwa  chikuru  cheongororo  ndechekuwana  ruzivo rutsva  runozobatsira  pane 
ramangwana. 
UNIVERSITY OF ZIMBABWE 
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 Hatingavimbisi  kuti ongororo iyi ichakubatsirai. 
 Munekodzero   yekuramba  kupinda/ kuve , kana yokubvuma  kupinda  izvozvi, uye  
yekushandura  pfungwa dzenyu pamberi  apo. 
 Chero  sarudzo  yamaita, hazvikanganisi  mabatirwo  enyu  enguva dzese 
 Ndapota  nyatsodzverai  chibvumirano  chino nemazvo.  Bvunzai  mibvunzo  musati  
maita  sarudzo- hamumanikidzwi  kupinda. 
 
 
Chinangwa  cheongororo 
Muri kukumbirwa  mvumo yekuti mwana wenyu apinde  muongororo  iyi nokuti  
muri  mubereki/ munhu  mukuru  anogara  mudunhu  rino.  Muongororo/  mutsvakiridzo  iyi  
tiri kuedza  kuona  zvinoitika kana  munhu  anwa mapiritsi anorapa bharaziya . Vana vari 
muzvikoro ndivo vachange vachipihwa mapiritsi aya, zvichireva izvo vanogona kubuda 
munyawiri muviri wese.    Isu vechirongwa chino tinoda kuongorora zvinokonzeresa 
munyawiri uyu. 
 
Mafambiro echirongwa 
Kana  mabvumidza mwana  kupinda  muongororo/tsvakirodzo  iyi  muchange  
murimumwe  wechikwata  chevanhu   vari munzvimbo dzakasiyasiyana vachange 
vachimirira vamwe vavo nezveongororo iyi yekuti vamwe vanobuda munyawiri asika vamwe 
hapanachinoitika. Tichabvunzazve vana vechikoro ava kuti tigoziva nzvimbo dzavanopinda 
mumvura. Izvi zvinotibatsira kuti tigoongorora kunobva chirwere ichi chebharazuya. 
 
Zvingangonetsa 
Hapana  zvinganetsa  pakupinda  muongororo  iyi.  Hurukuro  ingangotora  maminitsi 
mashanu kanasvika gumi enguva  yavena. Tichatorazve ropa ringanhoita sipunu rimwe kana 
maviri ekuti tizoshandisa kuongorora zviratidzwa zvwnyawiri urwu. 
 
Zvamunotarisirwa  kuwana 
Hapana  chatingati  muchawana  semuripo  nekuva  kwenyu  muongororo/tsvakiridzo  iyi. 
Muchawana  ruzivo  rutsva   runogona  kukubatsirai  kuchengetengetedza  mhuri  yenyu  iri 
mutano.  Zvekare,  pfungwa  dzenyu  nezvamakasanganirana nazvo  zvingangozobatsira  kuti 
kuve  nezvirongwa    zvirinani  zveutsana/kushambidzika  munharaunda yenyu kana  kune  
dzimwe  nzvimbo  dzenyika. 
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Muripo 
Hamubadharwe  kuva  muongororo iyi/ hapana muripo  nokuva  mutsvangiridzo  iyi. 
Zvichabuda  zvitsva  muongororo 
Tichagoverana  nemi zvichawanikwa  muongororo  ino  uye  zimwe  zvitsva zvatinenge 
tawana  pamusoro  pe tsvakiridzo iyi [yebharaziya nekurapwa kwayo nekubuda munyawiri]. 
Kuchengetedzwa kwezvinyorwa 
Tichanyora  pasi  zita  nekero  yenyu, nozvimwewo zviri maererano  nemi  pamapepa.  
Hapana  mumwe munhu   anogona kuona  zvinyorwa izvi  kunze  kwevari  muongororo.  
Tichashandisa  nhamba  kwete   zita,  kuti  vamwe  vakuzivei. Magwaro  ose  ane  zita nekero   
nezvimwe zviri maererano  nemi zvamuno tiudza  zvinochengetedzwa  zvakakiyirwa,  pane  
dzimwe  nguva  vaongorori   vemitano yeongorori  vangade  kuona  kuti  ongororo iri  kuitwa  
nemazvo  here,  ava  ndivo vangazotarisa   mapepa  aya.  Vanhu  ava  vanosanganisira   
veMedical  Research  Council  of  Zimbabwe kana kuti VeUniversity of Zimbabwe.  Vese  
ava  vanosungirwa  kuchengetedza  mazita  enyu  akavandika .  kuchengetedzwa  
kwakasimbisiswa hatingakukomakedze nekuti  mapepa emaresearch /ongororo  
haangadziviswi  kana achidiwa   navehurumende   kana  vematare  emutemo. Tichaedza 
nepatinogona kuchengetedza  zviri  maererano  nemi  zvakawandika.  Zvinobuda semhinduro  
yeongororo  iyi  kana  zvinoshambadzirwa, hazvibudi   zvine mazita  enyu  kana  remwana  
kana  zvimwe  zvinoita  kuti muzivikanwe  kuti  makanga  muri  mune  chino  chirongwa. 
 
Kuda  kwenyu 
Mwana haamanikidzwi  kupinda  muongororo  iyi.  Kana  masarudza  kuti apinde  
muongororo  iko  zvino  makasununguka  kumuti abude  muongororo  iyi  chero  nguva. 
 
Kana  muine  mibvunzo  monogona  kundibvunza  ndakasununguka  kuipindura.  
Munogonawo  kubvunza  vakuru  vakuru [Professor Takafira Mduluza] veongororo  vane  
mazita  akanyorwa  pazasi  apa  kana  paine   zvamusinganzwisisi  maererano  neongororo  
iyi  ikozvino  kana  mave  muongororo 
 
Ndivanaani  vandinofonera  kana  ndiine  mubvunzo  kana  dambudziko 
Kana  muine  mibvunzo  maererano  neongororo  taurai  navakuru  veongororo  vanonzi  
ma[principal  investigator]  [Tawanda Chisango]  panhamba dzinoti [0772731322] 
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Kana  muine mibvunzo  nezvekodzero  dzenyu  muchiongororo,  ridzai  rinhare  kune  
veMedical  Research Council of  Zimbabwe  
Josiah Tongogara/Mazoe  Street 
Causeway, Harare 
Telephone [04 791  193/ 7907 15/791791] 
 
Zvinorevei  kunyora [kusaina]  zita rako 
Ini , nyakusaina  pazasi, ndaudzwa  chinangwa, mafambiro,  zvingangonetsa  
nezvingangobatsira  muongororo  iyi.  Ndapihwa  rimwe  reiri  gwaro  rekugara naro.  
Ndapihwa  mukana wekubvunza  mibvunzo  chero nguva ipi  zvayo.  Ndazvisarudzira  uye 
ndabvuma kuti mwana ave  muongororo  iyi. Isarudzo yangu  kuti mwana abude  
muongororo, ndinoziva  kuti hazvikanganise  basa  rangu kana chinzvimbo  changu  
munharaunda. Ndinovimbisa   kuti ndichatevedza  zvandinenge  ndakumbirwa  kuita  
navashandi,  navakuru  vakuru veongororo  iyi. Ndinovimbisa kuudza  vashandi veongororo  
pakare  pakarepo  kana  ini  ndiine  zvinetswa pandinenge ndiri  muongororo. 
 
Zuva ramurikusainira mwana kupinda  muongororo,  zvichireva zuva  ranhasi, 
RINOFANIRWA  kunge  riri  mukati  memazuva  akaratidzwa  pachidhindo  chiri  
papepa  rimwe  nerimwe.  Mazuva  akaratidzwa  aya  anotaridza kuti  pepa rino  riri 
kufambiswa  munguva  yakatenderwa,  kureva  kuti  muchange  muri muongororo  iyi. 
 
 
   
Zita remwana (Nyorai nemavara makuru)   
 
    
Zita remubereki (Nyorai nemavara makuru)  Zuva 
 
     
Zita kana chiratidzo chearikumirira mwana Zuva nenguva  
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Hukama nemwana arikupinda muchirongwa 
 
____________________________________ ______________________________________________  
Hwitinesi – pane avo vasingagoni Zita remumiririri arikutora bvumo ino 
                  kuverenga kana kunyora 
  
Rimwe  remagwaro  echibvumirano  ichi  rakasainiwa  rinofanirwa  kuti 1]  
richengetedzwe  mufaira  nemukuru  mukuru weongororo ,2]  ripihwe  kune  uyo  
asarudza  kupinda  muongororo  ne3]   riiswe  mufaira  rekurapwa  kweuyo  asarudza  
kupinda  muongororo. 
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7.5: Informed consent form for parental consent 
   
  
 
MRCZ/A/1958  
 
INFORMED CONSENT FORM 
FOR PARENTAL CONSENT 
 
 
PROJECT TITLE 
Investigating Schistosomiasis Markers Of Inflammation And Immune Responses In 
Individuals On Repeated Mass Drug Administration 
 
Principal Investigator: Mr T Chisango (MSc)-0772731322 
Co-Investigator(s): Professor Takafira Mduluza, [PhD]- 0773633682 
    Dr B. Ndlovu. [PhD]- 27-31-788424574 
 
 
UNIVERSITY OF ZIMBABWE 
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ADD THE FOLLOWING PARAGRAPH TO ALL CONSENT FORMS  
MORE THAN TWO (2) PAGES LONG (BEFORE ADDITION OF THIS PARAGRAPH) 
 
What you should know about this research study: 
 We give you this consent so that you may read about the purpose, risks, and 
benefits of this research study. 
 
 Routine care is based upon the best known treatment and is provided with the 
main goal of helping the individual patient.  The main goal of research studies 
is to gain knowledge that may help future patients. 
 
 We cannot promise that this research will benefit your child.  Just like regular 
care, this research can have side effects that can be serious or minor. 
 
 You have the right to refuse to allow your child to take part, or agree for your 
child to take part now and change your mind later. 
 
 Whatever you decide, it will not affect your child’s regular care. 
 
 Please review this consent form carefully.  Ask any questions before you 
make a decision. 
 
 Your choice to allow your child to participate is voluntary. 
 
 
 
PURPOSE 
 You are being asked to allow your child to participate in a research study of bilharzia 
treatment and allergy.  The purpose of the study is to observe your child before and after 
treating bilharzia and observing if there is any development of allergy. Your child was 
selected as a possible participant in this study because this is the age that is commonly 
found infected with bilharzia and also their health and learning ability is greatly 
affected.Also the children at this school will get the treatment from the currently bilharzia 
treatment underway throughout the country. We need to monitor their health status before 
and after the treatment is given. The information is important in our country for any likely 
development of allergy as caused by the worms when they die after treatment. We would like 
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to get information for preparedness in the future activities of the mass treatment exercise by 
The Ministry of Health and Child Welfare.This study will have a total of about 600 
children recruited to represent others in the schools and we will have school children 
recruited from selected schools in other provinces. 
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PROCEDURES AND DURATION 
 If you decide to allow your child to participate, your child will be asked a few 
questions taking less than 5 minutes so that we know where they get in contact with water in 
rivers or streams and if there are things that cause allergy in their daily lives. Thereafter the 
child will be asked to provide urine and stool in small bottles so that we will be able to 
diagnose if they are infected with bilharzia and some worms. This process will be done over 
3 consecutive days so that we don’t miss any infection. A small blood sample 2,5 -5 mls will 
be taken from them and will used if they are infected with malaria and if there are markers 
that show any reaction to agents that cause allergy.  The same procedure will be conducted 
before they receive treatment and 6 weeks after treatment to observe any changes to treatment 
and the development of allergic markers. We will monitor the children for any development 
of allergy throughout the exercise of bilharzia and worms treatment every year for the next 5 
years.  
 
RISKS AND DISCOMFORTS 
 The study does not involve any risks besides a temporary discomfort that may be 
experienced by child while taking venous blood due to the needle prick. However, this 
procedure is a common and normal as practised at most health centres and will be performed 
by qualified medical personnel from the Ministry of Health.  
 
BENEFITS AND/OR COMPENSATION 
Your child will benefit from this program by being one of the few children that will receive 
close monitoring and examination from the mass treatment of bilharzia and worm throughout 
the country. The study team cannot manage to examine closely everyone, the reason we have 
to select a few to represent others.  
  
ALTERNATIVE PROCEDURES OR TREATMENTS 
 Praziquantel is the only drug available for treating bilharzia. Every child will receive 
this treatment for free. Treatment for the other worms would also be free.  
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CONFIDENTIALITY 
 If you indicate your willingness for your child to participate in this study by signing 
this document, any information that is obtained in connection with this study that can be 
identified with your child will remain confidential and will be disclosed only with your 
consent, and when appropriate, your child’s permission. Under some circumstances, the 
MRCZ and the local Institutional Review Board may need to review patient records for 
compliance audits. 
 
ADDITIONAL COSTS 
 There are no costs involved with this study 
 
IN THE EVENT OF INJURY 
 In the event of injury resulting from your child's participation in this study, treatment 
will be offered by the study.  
 
VOLUNTARY PARTICIPATION 
 Participation in this study is voluntary.  If you decide not to allow your child to 
participate in this study, your decision will not affect your or your child's future relations with 
research group and this institution, its personnel, and associated hospitals.  If you decide to 
allow your child to participate, you and your child are free to withdraw your consent and 
assent and discontinue participation at any time without penalty. 
 
ADDITIONAL ELEMENTS  
None 
 
 
 
 
MRCZ/A/1958 
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OFFER TO ANSWER QUESTIONS 
Before you sign this form, please ask any questions on any aspect of this study that is unclear 
to you.  You may take as much time as necessary to think it over. 
 
AUTHORIZATION 
YOU ARE MAKING A DECISION WHETHER OR NOT TO ALLOW YOUR CHILD TO 
PARTICIPATE IN THIS STUDY.  YOUR SIGNATURE INDICATES THAT YOU HAVE 
READ AND UNDERSTOOD THE INFORMATION PROVIDED ABOVE, HAVE HAD 
ALL YOUR QUESTIONS ANSWERED, AND HAVE DECIDED TO ALLOW YOUR 
CHILD TO PARTICIPATE. 
 
The date you sign this document to enroll your child in this study, that is, today’s date, 
MUST fall between the dates indicated on the approval stamp affixed to each page.  These 
dates indicate that this form is valid when you enroll your child in the study but do not reflect 
how long your child may participate in the study.  Each page of this Informed Consent Form 
is stamped to indicate the form’s validity as approved by the MRCZ. 
 
    
Name of Parent (please print)  Date 
 
 
     
Signature of Parent or legally authorized representative Time  
 
  
Relationship to the Participant 
 
 
____________________________________ ______________________________________________  
Signature of Witness Signature of Research Staff 
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(Optional)  
 
 YOU WILL BE GIVEN A COPY OF THIS CONSENT FORM TO KEEP. 
 
 If you have any questions concerning this study or consent form beyond those 
answered by the investigator, including questions about the research, your rights as a research 
Participant or research-related injuries; or if you feel that you have been treated unfairly and 
would like to talk to someone other than a member of the research team, please feel free to 
contact the Medical Research Council of Zimbabwe on telephone 791792 or 791193. 
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